<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        15-807-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN HCL 40MG/2ML CONC. FOR SOLU. FOR INF
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1232.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Zydus Hospira Oncology Private Limited ZHOPL " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Zydus Hospira Oncology Private Limited ZHOPL 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA UK LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX19 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Irinotecan Hydrochloride is an anticancer medicine containing the active substance irinotecan hydrochloride, trihydrate.</p><p>hydrochloride, trihydrate interferes with the growth and spread of cancer cells in the body.</p><p>&nbsp;</p><p>Irinotecan Hydrochloride is indicated in combination with other medicines for the treatment of patients with advanced or metastatic cancer of the colon or rectum.</p><p>may be used alone in patients with metastatic cancer of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Irinotecan Hydrochloride:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have chronic inflammatory bowel disease and/or bowel obstruction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to irinotecan hydrochloride trihydrate or any of the other ingredients of this medicine (listed in section 6 &ldquo;What Irinotecan Hydrochloride contains&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a breast-feeding woman (see section 2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your bilirubin level is higher than 3 times the upper limit of the normal range</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe bone marrow failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are in poor general condition (WHO performance status higher than 2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken St John&rsquo;s Wort (a herbal extract containing <em>Hypericum</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to take or have recently taken live attenuated vaccines (vaccines against yellow fever, chicken pox, shingles, measles, mumps, rubella, tuberculosis, rotavirus, influenza) and during the 6 months after stopping chemotherapy</p><p>&nbsp;</p><p>If you receive &nbsp;Irinotecan Hydrochloride in combination with other medicines, please make sure that you also read the package leaflet of the other medicines regarding additional contraindications.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Irinotecan Hydrochloride.</p><p>&nbsp;</p><p>Take special care with Irinotecan Hydrochloride. The use of Irinotecan Hydrochloride should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>&nbsp;</p><p><em><u>Diarrhoea</u></em></p><p>Irinotecan Hydrochloride can cause diarrhoea, which in some cases may be severe. This may start a few hours or a couple of days after the medicine infusion. If left untreated, it could lead to dehydration and serious chemical imbalances, which can be life threatening. Your doctor will prescribe medicine to help prevent or control this side effect. Make sure you get the medicine right away, so that you will have it at home when you need it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the medicine as prescribed at the first sign of loose or frequent bowel movements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drink large amounts of water and (or) salty drinks (fizzy water, soda or soup).</p><p>&nbsp;</p><p>Call your doctor or nurse if you still have diarrhoea, especially if it lasts more than 24&nbsp;hours, or if you get lightheaded, dizzy, or faint.</p><p>&nbsp;</p><p><em><u>Neutropenia (decrease in some white blood cells)</u></em></p><p>This medicine can lower your white blood cell count, mainly in the weeks after the medicine is given. This can increase the risk of getting an infection. Be sure to let your doctor or nurse know right away if you have any signs of infection, such as fever (38&nbsp;&deg;C or higher), chills, pain when passing urine, a new cough, or bringing up sputum. Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.</p><p>&nbsp;</p><p><em><u>Blood monitoring</u></em></p><p>Your doctor will likely test your blood before and during your treatment, to check for effects of the medicine on blood counts or on blood chemistry. Based on the test results, you may need medicines to help treat the effects. Your doctor may also need to reduce or delay your next dose of this medicine, or even stop it altogether. Keep all your appointments for doctor visits and lab tests.</p><p>&nbsp;</p><p>This medicine may lower your platelet count in the weeks after it is given, which can increase your risk of bleeding. Speak with your doctor before taking any medicines or supplements that might affect your body&rsquo;s ability to stop bleeding, such as aspirin or aspirin-containing medicines, warfarin, or vitamin E. Tell your doctor right away if you have unusual bruising, or bleeding such as nosebleeds, bleeding gums when you brush your teeth, or black, tarry stools.</p><p>&nbsp;</p><p><em><u>Nausea and vomiting</u></em></p><p>You may have nausea and vomiting on the day you receive this medicine or in the first few days after. Your doctor may give you medicine before your treatment to help prevent nausea and vomiting. Your doctor will likely prescribe anti-nausea medicines that you can take at home. Have these medicines on hand for when you need them. Call your doctor if you are unable to take fluids by mouth due to nausea and vomiting.</p><p>&nbsp;</p><p><em><u>Acute cholinergic syndrome</u></em></p><p>This medicine may affect part of your nervous system that controls body secretions, leading to what is known as cholinergic syndrome. Symptoms can include runny nose, increased saliva, excess tears in the eyes, sweating, flushing, abdominal cramps, and diarrhoea. Let your doctor or nurse know right away if you notice any of these symptoms, as there are medicines that can help control them.</p><p>&nbsp;</p><p><em><u>Lung disorders</u></em></p><p>Rarely, people on this medicine have serious lung problems. Tell your doctor right away if you have new or worsening cough, trouble breathing, and fever. Your doctor may need to stop your treatment to manage this problem.</p><p>&nbsp;</p><p>This medicine may increase your risk of major blood clots in the veins of the legs or lungs, which can travel to other parts of the body such as the lungs or brain. Tell your doctor right away if you notice chest pain, shortness of breath, or swelling, pain, redness, or warmth in an arm or leg.</p><p>&nbsp;</p><p><em><u>Chronic intestinal inflammation and/or intestinal blockage</u></em></p><p>Call your doctor if you have pain in your belly and you cannot move your bowels, especially if you also have bloating and loss of appetite.</p><p>&nbsp;</p><p><em><u>Irradiation therapy</u></em></p><p>If you recently received treatment with pelvic or abdominal radiotherapy, you may be at increased risk of developing bone marrow suppression. Please talk to your doctor before starting the Irinotecan Hydrochloride.</p><p>&nbsp;</p><p><em><u>Kidney function</u></em></p><p>Occurrences of kidney dysfunction have been reported.</p><p>&nbsp;</p><p><em><u>Cardiac disorders</u></em></p><p>Inform your doctor if you suffer/suffered from heart disease or if you previously received anticancer medicines. Your doctor will monitor you closely and discuss with you how risk factors (for example smoking, high blood pressure and to high fat content) can be reduced.</p><p>&nbsp;</p><p><em><u>Vascular disorders</u></em></p><p>Irinotecan Hydrochloride is rarely associated with blood flow disorders (blood clots in the vessels of your legs and lungs) and it may occur rarely in patients with multiple risks factors.</p><p>&nbsp;</p><p><em><u>Others</u></em></p><p>This medicine may cause sores in the mouth or on the lips, often within the first few weeks after starting treatment. This can cause mouth pain, bleeding, or even trouble eating. Your doctor or nurse can suggest ways to reduce this, such as changing the way you eat or how you brush your teeth. If needed, your doctor can prescribe medicine to help with the pain.</p><p>&nbsp;</p><p>Tell your doctor or dentist that you are on this medicine if you are planning to have surgery or any procedure.</p><p>&nbsp;</p><p>If used in combination with other anticancer medicines for your condition please make sure that you also read the leaflets for the other medicine.</p><p>&nbsp;</p><p>If you have &nbsp;been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>Other medicines and Irinotecan Hydrochloride</strong></p><p>Irinotecan Hydrochloride can interact with a number of medicines and supplements, which may either raise or lower the level of the medicine in your blood. Tell your doctor or pharmacist if you are using, have recently used or might use any of the following:</p><p>&nbsp;</p><ul><li>Medicines used to treat seizure (carbamazepine, phenobarbital, phenytoin and fosphenytoin)</li><li>Medicines used to treat fungal infection (ketoconazole, itraconazole, voriconazole and posaconazole)</li><li>Medicines used to treat bacterial infection (clarithromycine, erythromycin and telithromycine)</li><li>Medicines used to treat tuberculosis (rifampicin and rifabutin)</li><li>St. John&#39;s Wort (a herbal dietary supplement)</li><li>Live attenuated vaccines</li><li>Medicines used to treat HIV (indinavir, ritonavir, amprenavir, fosamprenavir, nelfinavir, atazanavir, and others)</li><li>Medicines used to suppress your body&rsquo;s immune system to prevent transplant rejection (cyclosporine and tacrolimus)</li><li>Medicines used to treat cancer (regorafenib, crizotinib, idelalisib and apalutamide)</li><li>Vitamin K antagonists (common blood thinner such as Warfarin)</li><li>Medicines used to relax muscles used during general anaesthesia and surgery (suxamethonium)</li><li>5-fluorouracil/folinic acid</li><li>Bevacizumab (a blood vessel growth inhibitor)</li><li>Cetuximab (an EGF receptor inhibitor)</li></ul><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse before being given Irinotecan Hydrochloride if you are already having, or have recently had chemotherapy (and radiotherapy).</p><p>&nbsp;</p><p>Don&#39;t start or stop taking any medicines while you are on Irinotecan Hydrochloride without talking with your doctor first.</p><p>&nbsp;</p><p>This medicine can cause serious diarrhoea. Try to avoid &nbsp;laxatives and stool softeners while taking this medicine.</p><p>&nbsp;</p><p>There may be more medicines that interact with Irinotecan Hydrochloride. Check with your doctor, pharmacist or nurse about your other medicines, herbs, and supplements, and whether alcohol can cause problems with this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>Women of childbearing potential and men have to use effective contraception during and up to 1&nbsp;month and 3&nbsp;months after treatment respectively.</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>This medicine may cause problems with the foetus if taken at the time of conception or during pregnancy. Men and women who are taking this medicine should use reliable birth control during treatment. It is important to check with your doctor about what kinds of birth control can be used with this medicine. In pregnant women, treatment with this medicine should be used only if the potential benefit to the mother outweighs the risk to the foetus.</p><p>&nbsp;</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><em><u>Breast-feeding</u></em></p><p>No studies have been done, nevertheless, this medicine may pass into breast milk and affect the baby. Breast-feeding should be discontinued for the duration of your treatment with this medicine.</p><p>&nbsp;</p><p>If you are breast-feeding, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><em><u>Fertility</u></em></p><p>No studies have been done, nevertheless, this medicine may affect fertility. Talk with your doctor about the possible risk with this medicine and the options that may preserve your ability to have children.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may notice that you are dizzy and/or have trouble with your vision in the first 24 hours or so after you take this medicine. Do not drive or operate machinery if you have this side effect.</p><p>&nbsp;</p><p><strong>This medicine contains</strong><strong> sorbitol </strong></p><p>This medicine contains a sugar (sorbitol). Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p>&nbsp;</p><p><strong>This medicine contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Irinotecan Hydrochloride will be given to you by healthcare professionals.</p><p>&nbsp;</p><p>Your doctor may recommend a DNA test before your first dose of Irinotecan Hydrochloride.</p><p>&nbsp;</p><p>Some people are genetically more likely to have certain side effects from the medicine.</p><p>&nbsp;</p><p>The amount of &nbsp;Irinotecan Hydrochloride that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.</p><p>&nbsp;</p><p>Irinotecan Hydrochloride is injected into a vein through an intravenous route (IV). You will receive this injection in a clinic or hospital setting. Irinotecan Hydrochloride must be given slowly, and the IV infusion can take up to 90&nbsp;minutes to complete.</p><p>&nbsp;</p><p>You may be given other medications to prevent nausea, vomiting, diarrhoea, and other side effects while you are receiving Irinotecan Hydrochloride. You may need to keep using these medicines for at least a day after your Irinotecan Hydrochloride injection.</p><p>&nbsp;</p><p>Tell your care givers if you feel any burning, pain, or swelling around the IV needle when Irinotecan Hydrochloride is injected. If the medicine escapes from the vein it can cause tissue damage. If you experience pain or notice redness or swelling at the IV site while you are receiving Irinotecan Hydrochloride, alert your healthcare professional immediately.</p><p>&nbsp;</p><p>There are currently several treatment schedules recommended for Irinotecan Hydrochloride. It is usually given either once every 3 weeks (Irinotecan Hydrochloride given alone) or once every 2 weeks (Irinotecan Hydrochloride given in combination with 5FU/FA chemotherapy). The dose will depend on a number of factors, including the treatment schedule, your body size, your age and general health, your blood counts, how well your liver is working, whether you have had radiation to your abdomen/pelvis, and whether you have any side effects such as diarrhoea.</p><p>&nbsp;</p><p>Only your doctor may assess the duration of treatment.</p><p>&nbsp;</p><p><strong>If you use more </strong><strong>Irinotecan Hydrochloride</strong><strong> than you should</strong></p><p>Seek emergency medical attention. Overdose symptoms may include some of the serious side effects listed in this medication guide.</p><p>&nbsp;</p><p><strong>If you forget to use </strong><strong>Irinotecan Hydrochloride</strong></p><p>Call your doctor for instructions if you miss an appointment for your Irinotecan Hydrochloride injection.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Some side effects could be serious. You must immediately contact your doctor if you experience any of those following serious side effects (see section 2).</p><p>&nbsp;</p><p>Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea (see section 2)</p><p>&sect;&nbsp;&nbsp;&nbsp; Early diarrhoea: Occurring within 24 hours of receiving this medicine, accompanied by symptoms runny nose, increased salivation, watery eyes, sweating, flushing, abdominal cramping.&nbsp;(This can occur while the medicine is being administered.&nbsp;If so, alert your healthcare professional promptly.&nbsp;Medication can be given to stop and/or lessen this early side effect).</p><p>&sect;&nbsp;&nbsp;&nbsp; Late diarrhoea: Occurring greater than 24 hours of receiving this medicine.&nbsp;Because of concerns of dehydration and electrolyte imbalances with diarrhoea it is important to be in contact with health care professionals for monitoring, and for medication and diet modifications&nbsp;advice.</p><p>&nbsp;</p><p>Talk to your doctor or nurse if you experience any of the symptoms below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Symptoms</strong></p></td><td style="vertical-align:top"><p><strong>Frequency<sup>*</sup> of occurrence in Monotherapy </strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong><sup>&dagger;</sup><strong> of occurrence in Combination Therapy</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Abnormally low number of white blood cells which could put you at increased risk for infection</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of red blood cells causing tiredness and shortness of breath</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Cholinergic syndrome (see Take special care with Irinotecan Hydrochloride)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hair loss (reversible)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Inflammation of mucous membranes</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Feeling weak and having no energy</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of platelets (blood cells that help with clotting) which may cause bruising or bleeding</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal liver function test values</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of white blood cells with fever</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Difficulty in passing stools</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal kidney function test values</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Not reported</p></td></tr></tbody></table><p><sup>*</sup> Very common: may affect more than 1 in 10 people</p><p>&nbsp;&nbsp;<sup>&dagger;</sup> Common: may affect up to 1 in 10 people</p><p>&nbsp;</p><p><strong>N</strong><strong>ot known</strong><strong>:</strong><strong> </strong><strong>frequency cannot be estimated from the available data</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe, persistent or bloody diarrhoea (which may be associated with stomach pain or fever) caused by bacteria called (<em>Clostridium difficile</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration (due to diarrhoea and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, rapid heartbeat and pale skin (a condition called hypovolaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary speech disorders during or shortly after treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pins and needles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure (during or after infusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung disease causing wheezing and shortness of breath (see section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal blockage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from the bowels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal lab test results</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hole in the intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatty liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions at the site where the medicine was administered</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of salt in the blood mostly related with diarrhoea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viral infections</p></td></tr></tbody></table><p>* Infrequent cases of these events have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or &nbsp;infections of the blood.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To Report any side effect:</strong></p><p><strong>&nbsp;</strong></p><p>Saudi Arabia :</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website:https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.<br />Shelf life: The shelf life of unopened vials is 3 years. Once opened, vials should be used immediately as they contain no antimicrobial preservatives.<br /><br />Do not store above 30&deg;C, Do not freeze<br />&nbsp;</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>Concentrate: Keep vials in the outer carton in order to protect from light. Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted concentrate: For single use only. Unused solution should be discarded</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following dilution: Chemical and physical in-use stability has been demonstrated in glucose 50 mg/ml (5%) and sodium chloride 9 mg/ml (0.9%) for 72 hours at 2-8 &deg;C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles visible in the concentrate or infusion solution.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is irinotecan hydrochloride, trihydrate. Each millilitre (ml) of solution contains 20 milligrams (mg) of irinotecan hydrochloride, trihydrate, equivalent to 17.33 mg irinotecan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sorbitol (E420), lactic acid, Water for Injections, and sodium hydroxide and hydrochloric acid (used to adjust pH).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Irinotecan Hydrochloride is in the form of a concentrate for solution for infusion (a concentrated solution which is diluted to make a solution which is given as a slow infusion via a drip). 

The medicine comes in glass containers called vials, containing 2 ml, 5 ml and 25 ml of irinotecan hydrochloride, trihydrate. 

The vials are wrapped in a protective plastic to reduce the risk of spillage if the vials break - these are referred to as ONCO-TAIN® vials. 

The vials are available in single packs. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Hospira UK Limited, United kingdom.</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>-&nbsp; Zydus Hospira Oncology Private Limited ZHOPL, Ahmedabad, India</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">هيدروكلوريد إرينوتيكان هو دواء مضاد للسرطان يحتوي على المادة الفعالة هيدروكلوريد إرينوتيكان، ثلاثي الهيدرات.</p><p dir="RTL">يتعارض هيدروكلوريد إرينوتيكان، ثلاثي الهيدرات مع نمو الخلايا السرطانية وانتشارها في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم هيدروكلوريد بالتزامن مع أدوية أخرى لعلاج المرضى المصابين بسرطان متقدم أو نقيلي في القولون أو المستقيم.</p><p dir="RTL">ويمكن استخدامه بمفرده لدى المرضى المصابين بسرطان نقيلي في القولون أو المستقيم الذين تكرر لديهم المرض أو تطور بعد العلاج الأولي الذي يعتمد على الفلورويوراسيل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال هيدروكلوريد إرينوتيكان:</strong></p><ul><li dir="RTL">إذا كنت تعاني من مرض الأمعاء الالتهابي المزمن و/أو انسداد الأمعاء</li><li dir="RTL">إذا كنت مصابًا بحساسية تجاه هيدروكلوريد إرينوتيكان ثلاثي الهيدرات أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦ &quot;ما هي محتويات هيدروكلوريد إرينوتيكان&quot;)</li><li dir="RTL">إذا كنتِ سيدة ترضع رضاعة طبيعية (انظري القسم ۲)</li><li dir="RTL">إذا كان مستوى البيليروبين لديك أعلى من ۳ أضعاف الحد الأقصى للنطاق الطبيعي</li><li dir="RTL">إذا كنت تعاني فشل النخاع العظمي الشديد</li><li dir="RTL">إذا كانت حالتك العامة سيئة (أعلى من ۲ على اختبار حالة الأداء الخاص بمنظمة الصحة العالمية)</li><li dir="RTL">إذا كنت تتناول أو سبق أن تناولت نبتة سانت جون (مستخلص عشبي يحتوي على هايبريكوم)</li><li dir="RTL">إذا كنت ستتلقى أو تلقيت مؤخرًا لقاحات حية موهنة (لقاحات ضد الحمى الصفراء، الجديري المائي، القوباء المنطقية، الحصبة، النكاف، الحصبة الألمانية، السل، فيروس الروتا، الإنفلونزا) خلال ٦ أشهر من توقف العلاج الكيميائي</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتلقى هيدروكلوريد إرينوتيكان بالتزامن مع أدوية أخرى، يُرجى أيضًا التأكد من قراءة النشرة الداخلية الخاصة بهذه الأدوية فيما يتعلق بموانع الاستعمال الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال هيدروكلوريد إرينوتيكان</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل استخدام هيدروكلوريد إرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توخ الحذر بشكل خاص عند استخدام هيدروكلوريد إرينوتيكان. ينبغي أن يكون استخدام هيدروكلوريد إرينوتيكان محدودًا على الوحدات المتخصصة في إعطاء العلاج الكيميائي السام للخلايا وينبغي أن يتم إعطاؤه فقط تحت إشراف طبيب مؤهل للتعامل مع العلاج الكيميائي المضاد للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الإسهال</u></em></p><p dir="RTL">يمكن أن يؤدي هيدروكلوريد إرينوتيكان إلى إسهال، وقد يكون شديدًا في بعض الحالات. قد يبدأ ذلك بعد بضع ساعات أو بضعة أيام من تسريب الدواء. إذا لم يُعالج، فقد يؤدي إلى جفاف واختلال خطير في التوازن الكيميائي، مما قد يهدد الحياة. سيصف لك طبيبك دواءً للمساعدة في منع أو التحكم في هذا العرض الجانبي. تأكد من حصولك على الدواء على الفور، بحيث يكون لديك في المنزل عندما تحتاجه.</p><ul><li dir="RTL">تناول الدواء الموصوف لك عند أول علامة على حركة أمعاء سائبة أو مستمرة.</li><li dir="RTL">اشرب كميات كبيرة من الماء و(أو) المشروبات المالحة (المياه الغازية أو الصودا أو الحساء).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك أو الممرضة إذا كنت لا تزال تعاني من الإسهال، وخاصةً إذا استمر ذلك لفترة أطول من ۲٤ ساعة، أو إذا شعرت بالدوخة أو الدوار أو فقدت الوعي.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em><u>قلة العدلات (انخفاض في بعض خلايا الدم البيضاء)</u></em></p><p dir="RTL">يمكن أن يسبب هذا الدواء انخفاضًا في تعداد خلايا الدم البيضاء، وبصفة رئيسية في الأسابيع التي تلي تلقي الدواء. يمكن أن يزيد ذلك من خطر الإصابة بعدوى. تأكد من إخبار طبيبك أو الممرضة فورًا إذا ظهرت عليك أي من علامات الإصابة بعدوى، على سبيل المثال، الحمى (۳۸ درجة مئوية أو أعلى) أو القشعريرة أو الشعور بألم عند التبول أو السعال الحديث أو وجود بلغم. تجنب التواجد بالقرب من الأشخاص المرضى أو المصابين بعدوى. أخبر طبيبك فورًا إذا ظهرت عليك علامات الإصابة بعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>مراقبة الدم</u></em></p><p dir="RTL">من المحتمل أن يقوم طبيبك بفحص دمك قبل العلاج وخلاله، للتحقق من آثار الدواء على تعداد الدم أو على كيمياء الدم. بناءً على نتائج الاختبار، قد تحتاج إلى أدوية للمساعدة في علاج الآثار. قد يضطر طبيبك أيضًا إلى تقليل أو تأخير جرعتك التالية من هذا الدواء، أو حتى إيقافه تمامًا. التزم بجميع مواعيدك الخاصة بزيارات الطبيب والاختبارات المعملية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل هذا الدواء من تعداد الصفائح الدموية في الأسابيع التي تلي تلقيه، مما قد يزيد من خطر النزيف. تحدث مع طبيبك قبل تناول أي أدوية أو مكملات قد تؤثر على قدرة جسمك على إيقاف النزيف، مثل الأسبرين أو الأدوية التي تحتوي على الأسبرين أو الوارفارين أو فيتامين هـ. أخبر طبيبك فورًا إذا كانت تعاني من كدمات غير عادية أو نزيف، مثل نزيف الأنف أو نزيف اللثة عند تنظيف الأسنان، أو براز أسود قطراني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الغثيان والقيء</u></em></p><p dir="RTL">قد تعاني من الغثيان والقيء في اليوم الذي تتلقى فيه هذا الدواء أو في الأيام القليلة الأولى بعد ذلك. قد يعطيك طبيبك دواءً قبل علاجك للمساعدة في منع الغثيان والقيء. من المحتمل أن يصف طبيبك أدوية مضادة للغثيان يمكنك تناولها في المنزل. احتفظ بهذه الأدوية في المتناول لحين الحاجة إليها. اتصل بطبيبك إذا كنت غير قادر على تناول السوائل عن طريق الفم بسبب الغثيان والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>المتلازمة الكولينية الحادة</u></em></p><p dir="RTL">قد يؤثر هذا الدواء على جزء من جهازك العصبي الذي يتحكم في إفرازات الجسم، مما يؤدي إلى ما يعرف بالمتلازمة الكولينية. يمكن أن تشمل الأعراض سيلان الأنف وزيادة اللعاب والدموع الزائدة في العين والعرق والاحمرار وتقلصات البطن والإسهال. أخبر طبيبك أو الممرضة على الفور إذا لاحظت أيًا من هذه الأعراض، حيث توجد أدوية يمكن أن تساعد في السيطرة عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>اضطرابات الرئتين</u></em></p><p dir="RTL">نادرًا ما يصاب الأشخاص الذين يتناولون هذا الدواء بمشكلات خطيرة في الرئتين. أخبر طبيبك في الحال إذا كنت تعاني من سعال جديد أو متفاقم، وصعوبة في التنفس، وحمى. قد يحتاج طبيبك إلى إيقاف علاجك للتعامل مع هذه المشكلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد هذا الدواء من خطر إصابتك بتخثرات دموية كبرى في أوردة الساقين أو الرئتين، ويمكن بدورها أن تنتقل إلى أجزاء أخرى من الجسم، مثل الرئتين أو الدماغ. أخبر طبيبك في الحال إذا شعرت بألم في الصدر، أو ضيق تنفس، أو تورم، أو ألم، أو احمرار، أو دفء في إحدى الذراعين أو الساقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الانسداد المعوي و/أو الالتهاب المعوي المزمن</u></em></p><p dir="RTL">اتصل بطبيبك إذا شعرت بألم في بطنك ولم تتمكن من التبرز، وخاصة إذا كنت تعاني أيضًا من الانتفاخ وفقدان الشهية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>العلاج الإشعاعي</u></em></p><p dir="RTL">إذا خضعت مؤخرًا لعلاج إشعاعي على الحوض أو البطن، فقد يزيد خطر إصابتك بكبت نخاع العظام. يُرجى التحدث مع طبيبك قبل بدء تلقي هيدروكلوريد إرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>وظائف الكلى</u></em></p><p dir="RTL">تم الإبلاغ عن حدوث حالات خلل وظيفي في الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>اضطرابات القلب</u></em></p><p dir="RTL">أخبر طبيبك إذا أصبت/كنت مصابًا بمرض في القلب أو إذا تلقيت سابقًا أدوية مضادة للسرطان. سيراقبك طبيبك عن كثب وسيناقش معك كيف يمكن تقليل عوامل الخطر (مثل التدخين، وضغط الدم المرتفع، والمحتوى العالي من الدهون).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الاضطرابات الوعائية</u></em></p><p dir="RTL">نادرًا ما يرتبط هيدروكلوريد إرينوتيكان باضطرابات تدفق الدم (تخثرات دموية في أوعية ساقيك ورئتيك)، وقد تحدث بشكل نادر لدى المرضى الذين لديهم عوامل خطر متعددة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>أخرى</u></em></p><p dir="RTL">قد يسبب هذا الدواء تقرحات في الفم أو على الشفتين، وغالبًا ما يكون ذلك خلال الأسابيع القليلة الأولى من بدء العلاج. يمكن أن يسبب هذا ألمًا في الفم، أو نزيفًا، أو حتى صعوبة في تناول الطعام. يمكن لطبيبك أو الممرضة اقتراح وسائل لتخفيف ذلك، مثل تغيير أسلوب تناولك للطعام أو كيفية غسلك لأسنانك. وإذا لزم الأمر، يمكن أن يصف طبيبك دواءً لتسكين الألم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو طبيب الأسنان الخاص بك أنك تستخدم هذا الدواء إذا كنت تخطط للخضوع إلى جراحة أو أي إجراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم استخدام هذا الدواء بالتزامن مع أدوية أخرى مضادة للسرطان لعلاج حالتك، يُرجى التأكد من قراءة نشرات الأدوية الأخرى أيضًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك أنك تعاني من عدم تحمل بعض السكريات، فتواصل معه قبل تناول هذا المنتج الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يمكن أن يتفاعل هيدروكلوريد إرينوتيكان مع عدد من الأدوية والمكملات التي يمكن أن ترفع أو تخفض مستوى الدواء في دمك. أخبر طبيبك أو الصيدلي إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيًا مما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج النوبات (كاربامازيبين، وفينوباربيتال، وفينيتوين، وفوسفينيتوين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى الفطرية (كيتوكونازول، وإيتراكونازول، وفوريكونازول، وبوساكونازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى البكتيرية (كلاريثروميسين، وإريثروميسين، وتيليثروميسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج السل (ريفامبيسين وريفابوتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون (مكمل غذائي عشبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات الحية الموهنة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية (HIV) (إندينافير، وريتونافير، وأمبرينافير، وفوسامبرينافير، ونيلفينافير، وأتازانافير، وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لكبت جهاز المناعة في جسمك لمنع رفض الزرع (سيكلوسبورين وتاكروليموس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج السرطان (ريجورافينيب، وكريزوتينيب، وإدياليسيب، وأبالوتاميد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات فيتامين ك (مسيلات الدم الشائعة مثل وارفارين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لإرخاء العضلات في أثناء التخدير العام والجراحة (سوكسميثونيوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥-فلورويوراسيل/حمض الفولينيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيفاسيزوماب (مثبط لنمو الأوعية الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتوكسيماب (أحد مثبطات مستقبلات عامل النمو البطاني (EGF))</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة قبل تلقي هيدروكلوريد إرينوتيكان إذا كنت تخضع بالفعل أو خضعت مؤخرًا للعلاج الكيميائي (والعلاج الإشعاعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تبدأ أو تتوقف عن تناول أي أدوية في أثناء تلقي هيدروكلوريد إرينوتيكان دون التحدث مع طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يسبب هذا الدواء إسهالًا شديدًا. حاول تجنب الملينات ومسهلات البراز في أثناء تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون هناك المزيد من الأدوية التي تتفاعل مع هيدروكلوريد إرينوتيكان. راجع طبيبك، أو الصيدلي، أو الممرضة بشأن الأدوية والأعشاب والمكملات الأخرى، وما إذا كان الكحول يمكن أن يسبب مشكلات مع هذا الدواء أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">ينبغي للنساء في سن الإنجاب والرجال استخدام وسيلة فعالة لمنع الحمل خلال العلاج وبعد انتهائه بشهر واحد و٣ أشهر، على التوالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الحمل</u></em></p><p dir="RTL">قد يسبب هذا الدواء مشكلات للجنين إذا تم تلقيه في وقت الإخصاب أو أثناء الحمل. يجب على الرجال والنساء الذين يتلقون هذا الدواء استخدام وسيلة فعالة لمنع الحمل في أثناء العلاج. من المهم مراجعة طبيبك حول أنواع وسائل منع الحمل التي يمكن استخدامها مع هذا الدواء. بالنسبة للنساء الحوامل، ينبغي عدم تلقي العلاج هذا الدواء إلا إذا كانت الفائدة التي قد تعود على الأم تفوق المخاطر على الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو تظنين أنكِ حامل أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا الدواء.</p><p dir="RTL"><em><u>&nbsp;</u></em></p><p dir="RTL"><em><u>الرضاعة</u></em></p><p dir="RTL">لم يتم إجراء أي دراسات، ومع ذلك، قد ينتقل هذا الدواء إلى حليب الأم ويؤثر على الطفل. ينبغي التوقف عن الرضاعة الطبيعية طوال فترة علاجكِ بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ تُرضعين، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الخصوبة</u></em></p><p dir="RTL">لم يتم إجراء أي دراسات، ومع ذلك، قد يؤثر هذا الدواء على الخصوبة. تحدث مع طبيبك حول المخاطر المحتملة لهذا الدواء والخيارات المتاحة التي قد تحافظ على قدرتك على الإنجاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير هيدروكلوريد إرينوتيكان على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بالدوار و/أو تواجه صعوبة في الرؤية في أول ٢٤ ساعة أو نحو ذلك بعد تلقي هذا الدواء. لا تقم بالقيادة أو تشغيل الآلات إذا أصبت بهذا العرض الجانبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات هيدروكلوريد إرينوتيكان</strong></p><p dir="RTL"><strong>يحتوي هذا الدواء على</strong> <strong>سوربيتول</strong></p><p dir="RTL">يحتوي هذا الدواء على سكر (سوربيتول). السوربيتول هو مصدر للفركتوز. إذا كنت (أنت أو طفلك) مصابًا بعدم تحمل الفركتوز الوراثي (HFI)، وهو اضطراب جيني نادر، يجب ألا تستخدم (أنت أو طفلك) هذا الدواء. المرضى المصابون بعدم تحمل الفركتوز الوراثي لا يستطيعون تكسير الفركتوز، وهو ما قد يسبب آثارًا جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إخبار طبيبك قبل تلقي هذا الدواء إذا كنت (أنت أو طفلك) مصابًا بعدم تحمل الفركتوز الوراثي أو إذا لم يعد طفلك قادرًا على تناول الأطعمة أو المشروبات الحلوة لأنه يشعر بالغثيان، أو يتقيأ، أو يشعر بآثار مزعجة مثل الانتفاخ، أو تقلصات المعدة، أو الإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي هذا الدواء على الصوديوم </strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. راجع طبيبك إذا لم تكن متأكدًا مما ينبغي عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاؤك هيدروكلوريد إرينوتيكان بواسطة أخصائيي رعاية صحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يوصي طبيبك بإجراء اختبار حمض نووي قبل تلقي جرعتك الأولى من هيدروكلوريد إرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يكون بعض الأشخاص أكثر عرضة وراثيًا للإصابة ببعض الأعراض الجانبية للدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد كمية هيدروكلوريد إرينوتيكان التي ستتلقاها على العديد من العوامل، بما في ذلك طولك ووزنك، وحالتك الصحية العامة أو غيرها من المشاكلات الصحية، ونوع السرطان أو الحالة التي يتم علاجها. سيحدد طبيبك جرعتك وجدول العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم حقن هيدروكلوريد إرينوتيكان في أحد الأوردة عبر المسار الوريدي (IV). ستتلقى هذا الحَقن في عيادة أو مستشفى. يجب إعطاء هيدروكلوريد إرينوتيكان ببطء، ويمكن أن يستغرق التسريب الوريدي ما يصل إلى ۹۰ دقيقة حتى ينتهي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم إعطاؤك أدوية أخرى للوقاية من الغثيان، والقيء، والإسهال، والأعراض الجانبية الأخرى في أثناء تلقيك هيدروكلوريد إرينوتيكان. قد تحتاج إلى الاستمرار في استخدام هذه الأدوية لمدة يوم واحد على الأقل بعد حَقن هيدروكلوريد إرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر مقدمي الرعاية الخاصين بك إذا شعرت بأي حرقان أو ألم أو تورم حول الإبرة الوريدية عند حقن هيدروكلوريد إرينوتيكان. إذا تسرب الدواء من الوريد، فقد يلحق تلفًا بالأنسجة. إذا شعرت بألم أو لاحظت احمرارًا أو تورمًا في موضع التسريب الوريدي في أثناء تلقيك هيدروكلوريد إرينوتيكان، فنبه أخصائي الرعاية الصحية الخاص بك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوجد حاليًا العديد من جداول العلاج الموصى بها لهيدروكلوريد إرينوتيكان. عادةً ما يتم إعطاؤه مرة كل ۳ أسابيع (يتم إعطاء هيدروكلوريد إرينوتيكان بمفرده) أو مرة كل أسبوعين (يتم إعطاء هيدروكلوريد إرينوتيكان بالتزامن مع العلاج الكيمائي ٥-فلورويوراسيل/حمض الفولينيك (5FU/FA)). ستعتمد الجرعة على عدد من العوامل، بما في ذلك جدول العلاج، وحجم جسمك، وعمرك، وحالتك الصحية العامة، وتعداد دمك، ومدى كفاءة عمل كبدك، وما إذا كنت قد تعرضت للإشعاع على منطقة بطنك/حوضك وما إذا كنت تعاني من أي أعراض جانبية مثل الإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فقط طبيبك من يمكنه أن يقيم مدة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من هيدروكلوريد إرينوتيكان</strong></p><p dir="RTL">اطلب العناية الطبية الطارئة. قد تشمل أعراض تلقي جرعة زائدة بعض الآثار الجانبية الخطيرة المدرجة في دليل الدواء هذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة هيدروكلوريد إرينوتيكان</strong></p><p dir="RTL">اتصل بطبيك للحصول على تعليمات إذا فاتك موعد حقن هيدروكلوريد إرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الأعراض الجانبية قد تكون خطيرة. يجب عليك التواصل مع طبيبك فورًا إذا عانيت من أي من تلك الأعراض الجانبية الخطيرة التالية (انظر القسم ۲).</p><p dir="RTL">&nbsp;</p><p dir="RTL">احصل على مساعدة طبية طارئة إذا أصبت بأي من تفاعلات الحساسية التالية: الشرى، أو صعوبة التنفس، أو تورم وجهك، أو شفتيك، أو لسانك، أو حلقك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال (انظر القسم ۲)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال المبكر: يحدث خلال ۲٤&nbsp;ساعة من تلقي هذا الدواء، مصحوبًا بأعراض سيلان الأنف، وزيادة إفراز اللعاب، والعيون الدامعة، والعرق، والاحمرار، وتقلصات البطن. (يمكن أن يحدث في أثناء تلقي الدواء. إذا كان الأمر كذلك، فنبه أخصائي الرعاية الصحية الخاص بك على وجه السرعة. يمكن إعطاء دواء لإيقاف و/أو الحد من هذا العرض الجانبي المبكر).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال المتأخر: يحدث بعد مرور أكثر من ۲٤&nbsp;ساعة على تلقي هذا الدواء. بسبب التخوف من حدوث الجفاف واضطرابات الكهارل مع الإسهال، من المهم أن تكون على تواصل مع أخصائيي الرعاية الصحية للمراقبة، وللحصول على نصائح بشأن الأدوية وتعديلات النظام الغذائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الممرضة إذا أصبت بأي من الأعراض أدناه:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>العرض</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>معدل<sup>*</sup> الحدوث في العلاج الأحادي</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>معدل</strong><strong><sup>&dagger; </sup></strong><strong>الحدوث في العلاج المركب</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد خلايا الدم البيضاء بشكل غير طبيعي مما قد يعرضك لخطر متزايد للإصابة بعدوى</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد خلايا الدم الحمراء مما يسبب التعب وضيق التنفس</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض الشهية</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المتلازمة الكولينية (انظر توخ الحذر بشكل خاص عند استخدام هيدروكلوريد إرينوتيكان)</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">القيء</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الغثيان</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ألم البطن</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تساقط الشعر (قابل للعكس)</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأغشية المخاطية</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الحمى</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الشعور بالضعف وانعدام الطاقة</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد الصفائح الدموية (خلايا الدم التي تساعد على التخثر) مما قد يسبب التكدم أو النزيف</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قيم غير طبيعية في اختبار وظائف الكبد</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">شائع جدًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">العدوى</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد خلايا الدم البيضاء المصحوب بالحمى</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">صعوبة في التبرز</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قيم غير طبيعية في اختبار وظائف الكلى</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">لم يتم الإبلاغ عنه</p></td></tr></tbody></table><p dir="RTL"><sup>*</sup> شائع جدًا: قد يصيب أكثر من شخص واحد من بين كل ۱۰ أشخاص</p><p dir="RTL"><sup>&dagger; </sup>شائع: قد يصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد أو المستمر أو الدموي (الذي قد يكون مصحوبًا بألم في المعدة أو حمى) تسببه بكتيريا تسمى المطثية العسيرة (كلوستريديوم ديفيسيل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف (نتيجة الإسهال والقيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار وضربات القلب السريعة وشحوب البشرة (حالة تسمى نقص حجم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات مؤقتة في الكلام أثناء العلاج أو بعده بفترة قصيرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس الشكشكة والوخز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع (أثناء التسريب أو بعده)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشكلات القلبية*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الرئة التي تسبب الأزيز وضيق التنفس (انظر القسم ۲)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الزغطة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانسداد المعوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم القولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في الاختبارات المعملية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث ثقب بالأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكبد الدهني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بالموضع الذي تم إعطاء الدواء فيه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأملاح في الدم مرتبط بالإسهال والقيء على الأغلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشكلات الكلوية*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المنخفض*</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفطرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفيروسية</p><p dir="RTL">* تمت ملاحظة حالات غير شائعة لهذه الأحداث في المرضى الذين أصيبوا بنوبات من الجفاف المرتبط بالإسهال و/أو القيء، أو حالات<em> </em>عدوى الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث مع طبيبك أو الصيدلي أو الممرضة بشأنها. يتضمن ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المملكة العربية السعودية:</p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;<strong>دول الخليج الأخرى:</strong></p><ul><li dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المُبين على الملصق وعلى العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.<br />مدة الصلاحية: مدة صلاحية القوارير غير المفتوحة ٣ سنوات. بمجرد فتح القوارير، ينبغي استخدامها على الفور حيث إنها لا تحتوي على مواد حافظة مضادة للميكروبات.<br />لا يخزن في درجة حرارة أعلى من 30 درجة مئوية، ولا يجمد.</p><p dir="RTL"><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>الرُكازة: احفظ القارورة في العبوة الكرتونية الخارجية من أجل حمايتها من الضوء. لا تقم بتجميده.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرُكازة المخففة: للاستخدام مرة واحدة فقط. ينبغي التخلص من المحلول غير المستخدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد التخفيف: تم إثبات استمرار الاستقرار الكيميائي والفيزيائي أثناء الاستخدام للركازة المخففة في محلول الجلوكوز تركيز ٥٠ ملجم/مل (٥ ٪) ومحلول كلوريد الصوديوم تركيز ٩ ملجم/مل (٠,٩ ٪) لمدة ٧٢ ساعة عند الحفظ في درجة حرارة تتراوح بين درجتين و٨ درجات مئوية. من وجهة نظر ميكروبيولوجية، ينبغي أن يستعمل المنتج على الفور. وإذا لم يستخدم فورًا، فإن مسؤولية مدة وظروف التخزين قبل الاستخدام تقع على عاتق المستخدم ويجب ألا تزيد هذه المدة في الطبيعي عن ٢٤ ساعة عند الحفظ في درجة حرارة تتراوح بين درجتين و٨ درجات مئوية ما لم يكن التخفيف قد تم في ظروف تعقيم تم التحكم فيها والتحقق منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت احتواءه على جسيمات مرئية في الركازة أو محلول التسريب الوريدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي هيدروكلوريد إرينوتيكان، ثلاثي الهيدرات. يحتوي كل ملليلتر (مل) واحد من المحلول على ٢٠ مليجرام (ملجم) من هيدروكلوريد إرينوتيكان، ثلاثي الهيدرات، ما يكافئ ١٧,٣٣ ملجم إرينوتيكان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي سوربيتول (E420)، وحمض اللاكتيك، وماء مخصص للحقن، وهيدروكسيد الصوديوم، وحمض الهيدروكلوريك (يُستخدم لتعديل مستوى الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تزويد هيدروكلوريد إرينوتيكان في صورة ركازة لتحضير محلول للتسريب الوريدى (محلول مركز يتم تخفيفه لإعداد محلول يتم إعطاؤه في صورة تسريب بطيء بالتنقيط).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تزويد الدواء في حاويات زجاجية تدعى قوارير، تحتوي على ٢ مل، و٥ مل، و٢٥ مل من هيدروكلوريد إرينوتيكان، ثلاثي الهيدرات.</p><p dir="RTL">تكون القوارير مغلفة ببلاستيك واقٍ لتقليل خطر الانسكاب إذا تعرضت القوارير للكسر - ويشار إليها بقوارير ONCO-TAIN<sup>&reg; </sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر القوارير في عبوات فردية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">Hospira UK Limited, United kingdom، المملكة المتحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; Zydus Hospira Oncology Private Limited ZHOPL, Ahmedabad,، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو/حزيران ٢٠٢١
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Irinotecan Hydrochloride 20 mg/ml concentrate for solution for infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The concentrate contains 20 mg/ml irinotecan hydrochloride, trihydrate (equivalent to 17.33 mg/ml irinotecan).

One vial of 2 ml contains 34.66 mg of irinotecan as 40 mg irinotecan hydrochloride, trihydrate (40 mg/2 ml).

One vial of 5 ml contains 86.65 mg of irinotecan as 100 mg irinotecan hydrochloride, trihydrate (100 mg/5 ml).

One vial of 25 ml contains 433.25 mg of irinotecan as 500 mg irinotecan hydrochloride, trihydrate (500 mg/25 ml).

Excipients with known effect

Sorbitol (E420): 45.0 mg/ml

Each 40 mg/2 ml vial contains 0.069 mg/ml of sodium (0.14 mg).

Each 100 mg/5 ml vial contains 0.071 mg/ml of sodium (0.35 mg).

Each 500 mg/25 ml vial contains 0.071 mg/ml of sodium (1.77 mg).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

A clear, colourless to pale yellow solution.

pH: 3.0 – 3.8

Osmolarity: 276 mOsm/kg. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.</p><p>&nbsp;</p><p>Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild‑type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (see section 5.1).</p><p>&nbsp;</p><p>Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.</p><p>&nbsp;</p><p>Irinotecan in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>For adults only. Diluted irinotecan solution for infusion should be infused into a peripheral or central vein.</p><p>&nbsp;</p><p><em>Recommended dosage:</em></p><p>&nbsp;</p><p>Dosages of irinotecan mentioned in this summary of product characteristics refer to mg of irinotecan hydrochloride, trihydrate.</p><p>&nbsp;</p><p><em><u>In monotherapy (for previously treated patient)</u></em></p><p><em><u>&nbsp;</u></em></p><p>The recommended dosage of irinotecan is 350 mg/m<sup>2 </sup>administered as an intravenous infusion over a 30 to 90 minute period every three weeks (see sections 4.4 and 6.6).</p><p>&nbsp;</p><p><em><u>In combination therapy (for previously untreated patient)</u></em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of irinotecan in combination with 5-fluorouracil (5FU) and folinic acid (FA) have been assessed in the following schedule (see section 5.1).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irinotecan plus 5FU/FA in every 2 weeks schedule</p><p>&nbsp;</p><p>The recommended dose of irinotecan is 180 mg/m<sup>2</sup> administered once every 2&nbsp;weeks as an intravenous infusion over a 30‑ to 90‑minute period, followed by an infusion of folinic acid and 5-fluorouracil.</p><p>&nbsp;</p><p>For the posology and method of administration of concomitant cetuximab, refer to the product information for this medicinal product.</p><p>&nbsp;</p><p>Normally, the same dose of irinotecan is used as administered in the last cycles of the prior irinotecan‑containing regimen. Irinotecan must not be administered earlier than 1 hour after the end of the cetuximab infusion.</p><p>&nbsp;</p><p>For the posology and method of administration of bevacizumab, refer to the bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>For the posology and method of administration of capecitabine combination, please see section 5.1 and refer to the appropriate sections in the capecitabine summary of product characteristics.</p><p>&nbsp;</p><p><em>Dosage adjustments:</em></p><p><u>&nbsp;</u></p><p>Irinotecan should be administered after appropriate recovery of all adverse events to Grade 0 or 1 NCI‑CTC (National Cancer Institute Common Toxicity Criteria) grading and when treatment-related diarrhoea is fully resolved.</p><p>&nbsp;</p><p>At the start of a subsequent infusion of therapy, the dose of irinotecan, and 5FU when applicable, should be decreased according to the worst grade of adverse events observed in the prior infusion. Treatment should be delayed by 1 to 2 weeks to allow recovery from treatment-related adverse events.</p><p>&nbsp;</p><p>With the following adverse events a dose reduction of 15 to 20% should be applied for irinotecan and/or 5FU when applicable:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haematological toxicity [neutropenia Grade 4, febrile neutropenia (neutropenia Grade 3-4 and fever Grade 2-4), thrombocytopenia and leukopenia (Grade 4)],</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-haematological toxicity (Grade 3-4).</p><p>&nbsp;</p><p>Recommendations for dose modifications of cetuximab when administered in combination with irinotecan must be followed according to the product information for this medicinal product.</p><p>&nbsp;</p><p>In combination with capecitabine for patients 65 years of age or more, a reduction of the starting dose of capecitabine to 800 mg/m<sup>2</sup> twice daily is recommended according to the summary of product characteristics for capecitabine. Refer also to the recommendations for dose modifications in combination regimen given in the summary of product characteristics for capecitabine.</p><p>&nbsp;</p><p><em>Treatment duration:</em></p><p>&nbsp;</p><p>Treatment with irinotecan should be continued until there is an objective progression of the disease or an unacceptable toxicity.</p><p><em><u>&nbsp;</u></em></p><p><em>Special populations:</em></p><p><u>&nbsp;</u></p><p><em><u>Patients with impaired hepatic function</u></em></p><p>&nbsp;</p><p><em>In monotherapy: </em></p><p>Blood bilirubin levels [up to 3 times the upper limit of the normal range (ULN)] in patients with performance status &pound;&nbsp;2, should determine the starting dose of irinotecan. In these patients with hyperbilirubinaemia and prothrombin time greater than 50%, the clearance of irinotecan is decreased (see section 5.2), and therefore the risk of hepatotoxicity is increased. Thus, weekly monitoring of complete blood counts should be conducted in this patient population.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with bilirubin levels up to 1.5 times the ULN, the recommended dosage of irinotecan is 350 mg/m<sup>2</sup>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with bilirubin levels between 1.5 to 3 times the ULN, the recommended dosage of irinotecan is 200 mg/m<sup>2</sup>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with bilirubin levels beyond 3 times the ULN, should not be treated with irinotecan (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>No data are available in patients with hepatic impairment treated with irinotecan in combination.</p><p>&nbsp;</p><p><em><u>Patients with impaired renal function</u></em></p><p>&nbsp;</p><p>Irinotecan is not recommended for use in patients with impaired renal function, as studies in this population have not been conducted (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em><u>Elderly</u></em></p><p>&nbsp;</p><p>No specific pharmacokinetic studies have been performed in the elderly. However, the dose should be chosen carefully in this population due to their greater frequency of decreased biological functions. This population should require more intense surveillance (see section 4.4).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>The safety and efficacy of irinotecan in children have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p><em>Precautions to be taken before handling or administering the medicinal product:</em></p><p><em>&nbsp;</em></p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Chronic inflammatory bowel disease and/or bowel obstruction (see section 4.4).
•	Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
•	Lactation (see section 4.6).
•	Bilirubin > 3 times the upper limit of the normal range (see section 4.4).
•	Severe bone marrow failure.
•	WHO performance status > 2.
•	Concomitant use with St John’s Wort (see section 4.5).
•	Live attenuated vaccines (see section 4.5).

For additional contraindications of cetuximab or bevacizumab or capecitabine, refer to the prescribing information for these medicinal products.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of irinotecan should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>&nbsp;</p><p>Given the nature and incidence of adverse events, irinotecan will only be prescribed in the following cases after the expected benefits have been weighed against the possible therapeutic risks:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with a risk factor, particularly those with a WHO performance status = 2.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the few rare instances where patients are deemed unlikely to observe recommendations regarding management of adverse events (need for immediate and prolonged anti-diarrhoeal treatment combined with high fluid intake at onset of delayed diarrhoea). Strict hospital supervision is recommended for such patients.</p><p>&nbsp;</p><p>When irinotecan is used in monotherapy, it is usually prescribed using the every‑3-week dosage schedule. However, the weekly-dosage schedule (see section 5) may be considered in patients who need a closer follow-up or who are at particular risk of severe neutropenia.</p><p>&nbsp;</p><p><u>Delayed diarrhoea </u></p><p>&nbsp;</p><p>Patients should be made aware of the risk of delayed diarrhoea occurring more than 24&nbsp;hours after the administration of irinotecan and at any time before the next cycle. In monotherapy, the median time of onset of the first liquid stool was on day&nbsp;5 after the infusion of irinotecan. Patients should quickly inform their physician of its occurrence and start appropriate therapy immediately.</p><p>&nbsp;</p><p>Patients with an increased risk of diarrhoea are those who have had previous abdominal/pelvic radiotherapy, those with baseline hyperleucocytosis, those with performance status &ge;&nbsp;2 and women. If not properly treated, diarrhoea can be life‑threatening, especially if the patient is concomitantly neutropenic.</p><p>&nbsp;</p><p>As soon as the first liquid stool occurs, the patient should start drinking large volumes of beverages containing electrolytes, and an appropriate anti-diarrhoeal therapy must be initiated immediately. The anti-diarrhoeal treatment will be prescribed by the department where irinotecan has been administered. After discharge from the hospital, the patients should obtain the prescribed medicinal products so they can treat the diarrhoea as soon as it occurs. In addition, they must inform their physician or the department administering irinotecan when/if diarrhoea is occurring.</p><p>&nbsp;</p><p>The currently recommended anti-diarrhoeal treatment consists of high doses of loperamide (4 mg at the first intake and then 2 mg every 2 hours). This therapy should continue for 12 hours after the last liquid stool and should not be modified. In no instance should loperamide be administered for more than 48&nbsp;consecutive hours at these doses, because of the risk of paralytic ileus, nor for less&nbsp;than&nbsp;12 hours.</p><p>&nbsp;</p><p>In addition to the anti-diarrhoeal treatment, a prophylactic broad-spectrum antibiotic should be given when diarrhoea is associated with severe neutropenia (neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>).</p><p>&nbsp;</p><p>In addition to the antibiotic treatment, hospitalisation is recommended for management of the diarrhoea in the following cases:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea associated with fever,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea (requiring intravenous hydration),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea persisting beyond 48 hours following the initiation of high‑dose loperamide therapy.</p><p>&nbsp;</p><p>Loperamide should not be given prophylactically, even in patients who experienced delayed diarrhoea at previous cycles.</p><p>&nbsp;</p><p>In patients who experienced severe diarrhoea, a reduction in dose is recommended for subsequent cycles (see section 4.2).</p><p>&nbsp;</p><p><u>Haematology</u></p><p>&nbsp;</p><p>In clinical studies, the frequency of NCI CTC Grade 3 and 4 neutropenia has been significantly higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation. Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more have also had a significantly greater likelihood of experiencing first-cycle Grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL.</p><p>&nbsp;</p><p>Weekly monitoring of complete blood cell counts is recommended during irinotecan treatment. Patients should be aware of the risk of neutropenia and the significance of fever. Febrile neutropenia (temperature &gt;&nbsp;38&deg;C and neutrophil count &le;&nbsp;1,000 cells/mm<sup>3</sup>) should be urgently treated in the hospital with broad-spectrum intravenous antibiotics.</p><p>&nbsp;</p><p>In patients who experienced severe haematological events, a dose reduction is recommended for subsequent administration (see section 4.2).</p><p>&nbsp;</p><p>There is an increased risk of infections and haematological toxicity in patients with severe diarrhoea. In patients with severe diarrhoea, complete blood cell counts should be performed.</p><p>&nbsp;</p><p><u>Liver impairment</u></p><p><u>&nbsp;</u></p><p>Liver function tests should be performed at baseline and before each cycle.</p><p>&nbsp;</p><p>Weekly monitoring of complete blood counts should be conducted in patients with bilirubin ranging from 1.5 to 3 times the ULN, due to decrease of the clearance of irinotecan (see section 5.2) and thus increasing the risk of hepatotoxicity in this population. For patients with a bilirubin &gt;&nbsp;3 times the ULN, see section 4.3.</p><p>&nbsp;</p><p><u>Nausea and vomiting</u></p><p><em>&nbsp;</em></p><p>A prophylactic treatment with antiemetics is recommended before each treatment with irinotecan. Nausea and vomiting have been frequently reported. Patients with vomiting associated with delayed diarrhoea should be hospitalised as soon as possible for treatment.</p><p><em><u>&nbsp;</u></em></p><p><u>Acute cholinergic syndrome</u></p><p>&nbsp;</p><p>If acute cholinergic syndrome appears (defined as early diarrhoea and various other signs and symptoms such as sweating, abdominal cramping, myosis and salivation), atropine sulphate (0.25 mg subcutaneously) should be administered unless clinically contraindicated (see section 4.8).</p><p>&nbsp;</p><p>These symptoms may be observed during or shortly after infusion of irinotecan, are thought to be related to the anticholinesterase activity of the irinotecan parent compound, and are expected to occur more frequently with higher irinotecan doses.</p><p>&nbsp;</p><p>Caution should be exercised in patients with asthma. If the patient experiences an acute and severe cholinergic syndrome, the use of prophylactic atropine sulphate is recommended with subsequent doses of irinotecan.</p><p>&nbsp;</p><p><u>Respiratory disorders</u></p><p><em><u>&nbsp;</u></em></p><p>Interstitial lung disease presenting as lung infiltration is uncommon during irinotecan therapy. Interstitial lung disease can be fatal. Risk factors possibly associated with the development of interstitial lung disease include the use of pneumotoxic medicinal products, radiation therapy and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during irinotecan therapy.</p><p>&nbsp;</p><p><u>Extravasation </u></p><p>&nbsp;</p><p>While irinotecan is not a known vesicant, care should be taken to avoid extravasation and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site and application of ice is recommended.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><em>&nbsp;</em></p><p>Due to the greater frequency of decreased biological functions, in particular hepatic function, in elderly patients, dose selection with irinotecan should be cautious in this population (see section 4.2).</p><p>&nbsp;</p><p><u>Chronic inflammatory bowel disease and/or bowel obstruction</u></p><p>&nbsp;</p><p>Patients must not be treated with irinotecan until resolution of the bowel obstruction (see section 4.3).</p><p>&nbsp;</p><p><u>Renal function</u></p><p><em>&nbsp;</em></p><p>Increases in serum creatinine or blood urea nitrogen have been observed. There have been cases of acute renal failure. These events have generally been attributed to complications of infection or to dehydration related to nausea, vomiting, or diarrhoea. Rare instances of renal dysfunction due to tumour lysis syndrome have also been reported.</p><p>&nbsp;</p><p><u>Irradiation therapy</u></p><p>&nbsp;</p><p>Patients who have previously received pelvic/abdominal irradiation are at increased risk of myelosuppression following the administration of irinotecan. Physicians should use caution in treating patients with extensive prior irradiation (e.g. &gt;&nbsp;25% of bone marrow irradiated and within 6&nbsp;weeks prior to start of treatment with irinotecan). Dosing adjustment may apply to this population (see section 4.2).</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>&nbsp;</p><p>Myocardial ischaemic events have been observed following irinotecan therapy predominately in patients with underlying cardiac disease, other known risk factors for cardiac disease, or previous cytotoxic chemotherapy (see section 4.8).</p><p>&nbsp;</p><p>Consequently, patients with known risk factors should be closely monitored, and action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).</p><p>&nbsp;</p><p><u>Vascular disorders</u></p><p>has been rarely associated with thromboembolic events (pulmonary embolism, venous thrombosis, and arterial thromboembolism) in patients presenting with multiple risk factors in addition to the underlying neoplasm.</p><p>&nbsp;</p><p><u>Others</u></p><p><u>&nbsp;</u></p><p>Concomitant administration of irinotecan with a strong inhibitor (e.g. ketoconazole) or inducer (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, apalutamide) of CYP3A4 may alter the metabolism of irinotecan and should be avoided (see section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p>Infrequent cases of renal insufficiency, hypotension or circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or sepsis.</p><p>&nbsp;</p><p>Women of childbearing potential and men have to use effective contraception during and up to 1&nbsp;month and 3 months after treatment respectively.</p><p>&nbsp;</p><p>This medicine contains sorbitol. Sorbitol is a source of fructose. Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly necessary. A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.</p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use contraindicated (see section 4.3)</u></p><p>&nbsp;</p><p><em>Saint John&rsquo;s Wort:</em> Decrease in the active metabolite of irinotecan, SN-38, plasma levels. In a small pharmacokinetic study (n&nbsp;=&nbsp;5), in which irinotecan 350 mg/m<sup>2</sup> was co-administered with St. John&#39;s Wort (<em>Hypericum perforatum</em>) 900 mg, a 42% decrease in the active metabolite of irinotecan, SN-38, plasma concentrations was observed. As a result, St. John&#39;s Wort should not be administered with irinotecan.</p><p>&nbsp;</p><p><em>Live attenuated vaccines (e.g. yellow fever vaccine): </em>Risk of generalised reaction to vaccines, possibly fatal. Concomitant use is contraindicated during treatment with irinotecan and for 6 months following discontinuation of chemotherapy. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>&nbsp;</p><p><u>Concomitant use not recommended (see section 4.4)</u></p><p>&nbsp;</p><p>Concurrent administration of irinotecan with strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) may alter the metabolism of irinotecan and should be avoided (see section 4.4).</p><p>&nbsp;</p><p><em>Strong CYP3A4 and/or UGT1A1 inducing medicinal products (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin or apalutamide): </em>Risk of reduced exposure to irinotecan, SN-38 and SN-38 glucuronide and reduced pharmacodynamic effects. Several studies have shown that concomitant administration of CYP3A4-inducing anticonvulsant medicinal products leads to reduced exposure to irinotecan, SN-38 and SN-38 glucuronide and reduced pharmacodynamic effects. The effects of such anticonvulsant medicinal products were reflected by a decrease in AUC of SN-38 and SN-38G by 50% or more. In addition to induction of CYP3A4 enzymes, enhanced glucuronidation and enhanced biliary excretion may play a role in reducing exposure to irinotecan and its metabolites. Additionally with phenytoin: Risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal products.</p><p>&nbsp;</p><p><em>Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, protease inhibitors, clarithromycin, erythromycin, telithromycin): </em>A study has shown that the co-administration of ketoconazole resulted in a decrease in the AUC of APC of 87% and in an increase in the AUC of SN-38 of 109% in comparison to irinotecan given alone.</p><p>&nbsp;</p><p><em>UGT1A1 inhibitors</em><em> (e.g. </em><em>atazanavir, ketoconazole, regorafenib): </em>Risk to increase systemic exposure to SN-38, the active metabolite of irinotecan. Physicians should take this into consideration if the combination is unavoidable.</p><p>&nbsp;</p><p><em>Other CYP3A4 inhibitors (e.g. crizotinib, idelalisib): </em>Risk of increase in irinotecan toxicity, due to a decrease in irinotecan metabolism by crizotinib or idelalisib.</p><p>&nbsp;</p><p><u>Caution for use </u></p><p><u>&nbsp;</u></p><p><em>Vitamin K antagonists:</em><strong> </strong>Increased risk of haemorrhage and thrombotic events in tumoural diseases. If vitamin K antagonists are indicated, an increased frequency in the monitoring of INR (International Normalised Ratio) is required.</p><p>&nbsp;</p><p><u>Concomitant use to take into consideration</u></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><em>Immunodepressant agents (e.g. ciclosporine, tacrolimus):</em> Excessive immunosuppression with risk of lymphoproliferation.</p><p>&nbsp;</p><p><em>Neuromuscular blocking agents:</em> Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Since irinotecan has anticholinesterase activity, medicinal products with anticholinesterase activity may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarising medicinal products may be antagonised.</p><p>&nbsp;</p><p><u>Other combinations</u></p><p><u>&nbsp;</u></p><p><em>5-fluorouracil/folinic acid:</em> Co-administration of 5-fluorouracil/folinic acid in the combination regimen does not change the pharmacokinetics of irinotecan.</p><p>&nbsp;</p><p><em>Bevacizumab:</em> Results from a dedicated drug-drug interaction trial demonstrated no significant effect of bevacizumab on the pharmacokinetics of irinotecan and its active metabolite SN-38. However, this does not preclude any increase of toxicities due to their pharmacological properties.</p><p>&nbsp;</p><p><em>Cetuximab:</em> There is no evidence that the safety profile of irinotecan is influenced by cetuximab or vice versa.</p><p>&nbsp;</p><p><em>Antineoplastic agents (including flucytosine as a prodrug for 5-fluorouracil):</em> Adverse effects of irinotecan, such as myelosuppression, may be exacerbated by other antineoplastic agents having a similar adverse-effect profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>&nbsp;</p><p>Women of childbearing potential and men have to use effective contraception during and up to 1&nbsp;month and 3 months after treatment respectively.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of irinotecan in pregnant women. Irinotecan has been shown to be embryotoxic and teratogenic in animals. Therefore, based on results from animal studies and the mechanism of action of irinotecan, irinotecan should not be used during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>In lactating rats, 14C-irinotecan was excreted in milk. It is unknown whether irinotecan is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breast‑feeding should be discontinued for the duration of irinotecan therapy (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no human data on the effect of irinotecan on fertility. In animals adverse effects of irinotecan on the fertility of offspring has been documented (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irinotecan has moderate influence on the ability to drive and use machines. Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of irinotecan, and advised not to drive or operate machinery if these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical Studies</u></p><p>&nbsp;</p><p>Adverse reaction data have been extensively collected from studies in metastatic colorectal cancer; the frequencies are presented below. The adverse reactions for other indications are expected to be similar to those for colorectal cancer.</p><p><strong>&nbsp;</strong></p><p>The most common (&ge;&nbsp;1/10), dose-limiting adverse reactions of irinotecan are delayed diarrhoea (occurring more than 24 hours after administration) and blood disorders including neutropenia, anaemia and thrombocytopenia.</p><p>&nbsp;</p><p>Neutropenia is a dose-limiting toxic effect. Neutropenia was reversible and not cumulative; the median day to nadir was 8&nbsp;days whatever the use in monotherapy or in combination therapy.</p><p><strong>&nbsp;</strong></p><p>Very commonly severe transient acute cholinergic syndrome was observed.</p><p>&nbsp;</p><p>The main symptoms were defined as early diarrhoea and various other symptoms such as abdominal pain, sweating, myosis and increased salivation occurring during or within the first 24&nbsp;hours after the infusion of irinotecan. These symptoms disappear after atropine administration (see section 4.4).</p><p>&nbsp;</p><p><u>Monotherapy</u></p><p>&nbsp;</p><p>The following adverse reactions considered to be possibly or probably related to the administration of irinotecan have been reported from 765&nbsp;patients at the recommended dose of 350&nbsp;mg/m<sup>2</sup> in monotherapy. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common (&sup3;&nbsp;1/10), common (&sup3;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&sup3;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), and very rare (&lt;&nbsp;1/10,000).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Adverse Reactions Reported with Irinotecan in Monotherapy (350 mg/m<sup>2</sup> every 3 weeks schedule) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category </strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cholinergic syndrome</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia (reversible)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Mucosal inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases (ALT and AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Description of selected adverse reactions (monotherapy):</em></p><p><strong>&nbsp;</strong></p><p><strong>Severe diarrhoea</strong> was observed in 20% of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 14% have severe diarrhoea. The median time of onset of the first liquid stool was on day&nbsp;5 after the infusion of irinotecan.</p><p>&nbsp;</p><p><strong>Nausea and vomiting</strong> were severe in approximately 10% of patients treated with antiemetics.</p><p>&nbsp;</p><p><strong>Constipation</strong> has been observed in less than 10% of patients.</p><p>&nbsp;</p><p><strong>Neutropenia</strong> was observed in 78.7% of patients and was severe (neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) in 22.6% of patients. Of the evaluable cycles, 18% had a neutrophil count below 1,000&nbsp;cells/mm<sup>3</sup> including 7.6% with a neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>.</p><p>&nbsp;</p><p>Total recovery was usually reached by day&nbsp;22.</p><p>&nbsp;</p><p><strong>Febrile neutropenia</strong> was reported in 6.2% of patients and in 1.7% of cycles.</p><p>&nbsp;</p><p><strong>Infections</strong> occurred in about 10.3% of patients (2.5% of cycles) and were associated with severe neutropenia in about 5.3% of patients (1.1% of cycles), and resulted in death in 2&nbsp;cases.</p><p>&nbsp;</p><p><strong>Anaemia</strong> was reported in about 58.7% of patients (8% with haemoglobin &lt;&nbsp;8&nbsp;g/dl and 0.9% with haemoglobin &lt;&nbsp;6.5&nbsp;g/dl).</p><p>&nbsp;</p><p><strong>Thrombocytopenia</strong> (&lt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>) was observed in 7.4% of patients and 1.8% of cycles with 0.9% with platelets count &pound;&nbsp;50,000&nbsp;cells/mm<sup>3 </sup>and 0.2% of cycles.</p><p>&nbsp;</p><p>Nearly all the patients showed a recovery by day&nbsp;22.</p><p>&nbsp;</p><p><strong>Acute cholinergic syndrome </strong>Severe transient acute cholinergic syndrome was observed in 9% of patients treated in monotherapy.</p><p>&nbsp;</p><p><strong>Asthenia</strong> was severe in less than 10% of patients treated in monotherapy. The causal relationship to irinotecan has not been clearly established.</p><p>&nbsp;</p><p><strong>Pyrexia</strong> in the absence of infection and without concomitant severe neutropenia, occurred in 12% of patients treated in monotherapy.</p><p>&nbsp;</p><p><strong>Laboratory tests</strong> Transient and mild to moderate increases in serum levels of either transaminases, alkaline phosphatase or bilirubin were observed in 9.2%, 8.1% and 1.8% of the patients, respectively, in the absence of progressive liver metastasis.</p><p>&nbsp;</p><p>Transient and mild to moderate increases of serum levels of creatinine have been observed in 7.3% of the patients.</p><p><u>&nbsp;</u></p><p><u>Combination Therapy</u></p><p><strong>&nbsp;</strong></p><p>Adverse reactions detailed in this section refer to irinotecan.</p><p>&nbsp;</p><p>There is no evidence that the safety profile of irinotecan is influenced by cetuximab or <em>vice versa</em>. In combination with cetuximab, additional reported adverse reactions were those expected with cetuximab (such as dermatitis acneiform 88%). For information on adverse reactions on irinotecan in combination with cetuximab, also refer to their respective summary of product characteristics.</p><p>&nbsp;</p><p>Adverse drug reactions reported in patients treated with capecitabine in combination with irinotecan in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy include: <em>Very common, all grade adverse drug reactions</em>: thrombosis/embolism; <em>Common, all grade adverse drug reactions: </em>hypersensitivity, myocardial ischaemia/infarction; <em>Common, Grade 3 and Grade 4 adverse drug reactions</em>: febrile neutropenia. For complete information on adverse reactions of capecitabine, refer to the capecitabine summary of product characteristics.</p><p>&nbsp;</p><p>Grade 3 and Grade 4 adverse drug reactions reported in patients treated with capecitabine in combination with irinotecan and bevacizumab in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy include: <em>Common, Grade 3 and Grade 4 adverse drug reactions: </em>neutropenia, thrombosis/embolism, hypertension, and myocardial ischaemia/infarction. For complete information on adverse reactions of capecitabine and bevacizumab, refer to the respective capecitabine and bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>Grade 3 hypertension was the principal significant risk involved with the addition of bevacizumab to bolus irinotecan/5FU/FA. In addition, there was a small increase in the Grade 3/4 chemotherapy adverse events of diarrhoea and leukopenia with this regimen compared to patients receiving bolus irinotecan/5FU/FA alone. For other information on adverse reactions in combination with bevacizumab, refer to the bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>Irinotecan has been studied in combination with 5FU and FA for metastatic colorectal cancer.</p><p>&nbsp;</p><p>Safety data of adverse reactions from clinical studies demonstrate very commonly observed NCI Grade 3 or 4 possibly or probably-related adverse events in the blood and the lymphatic system disorders, gastrointestinal disorders, and skin and subcutaneous tissue disorders MedDRA System Organ Classes.</p><p><strong>&nbsp;</strong></p><p>The following adverse reactions considered to be possibly or probably related to the administration of irinotecan have been reported from 145 patients treated by irinotecan in combination therapy with 5FU/FA in every 2&nbsp;weeks schedule at the recommended dose of 180&nbsp;mg/m<sup>2</sup>.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Adverse Reactions Reported with Irinotecan in Combination Therapy (180 mg/m<sup>2</sup> every 2 weeks schedule) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category </strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cholinergic syndrome</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia (reversible)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Mucosal inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminases (ALT and AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Description of selected adverse reactions (combination therapy):</em></p><p><strong>&nbsp;</strong></p><p><strong>Severe diarrhoea</strong> was observed in 13.1% of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 3.9% have a severe diarrhoea.</p><p>&nbsp;</p><p>A lower incidence of severe <strong>nausea and vomiting</strong> was observed (2.1% and 2.8% of patients respectively).</p><p>&nbsp;</p><p><strong>Constipation</strong> relative to irinotecan and/or loperamide has been observed in 3.4% of patients.</p><p>&nbsp;</p><p><strong>Neutropenia</strong> was observed in 82.5% of patients and was severe (neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) in 9.8% of patients. Of the evaluable cycles, 67.3% had a neutrophil count below 1,000&nbsp;cells/mm<sup>3</sup> including 2.7% with a neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>. Total recovery was usually reached within 7‑8 days.</p><p>&nbsp;</p><p><strong>Febrile neutropenia</strong> was reported in 3.4% of patients and in 0.9% of cycles.</p><p>&nbsp;</p><p><strong>Infections</strong> occurred in about 2% of patients (0.5% of cycles) and were associated with severe neutropenia in about 2.1% of patients (0.5% of cycles), and resulted in death in 1&nbsp;case.</p><p>&nbsp;</p><p><strong>Anaemia</strong> was reported in 97.2% of patients (2.1% with haemoglobin &lt;&nbsp;8&nbsp;g/dl).</p><p>&nbsp;</p><p><strong>Thrombocytopenia</strong> (&lt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>) was observed in 32.6% of patients and 21.8% of cycles. No severe thrombocytopenia (&lt;&nbsp;50,000&nbsp;cells/mm<sup>3</sup>) has been observed.</p><p>&nbsp;</p><p><strong>Acute cholinergic syndrome</strong> Severe transient acute cholinergic syndrome was observed in 1.4% of patients treated in combination therapy.</p><p>&nbsp;</p><p><strong>Asthenia </strong>was severe in 6.2% of patients treated in combination therapy. The causal relationship to irinotecan has not been clearly established.</p><p><strong>&nbsp;</strong></p><p><strong>Pyrexia in the absence of infection</strong> and without concomitant severe neutropenia, occurred in 6.2% of patients treated in combination therapy.</p><p>&nbsp;</p><p><strong>Laboratory tests </strong>Transient serum levels (Grades 1 and 2) of either SGPT, SGOT, alkaline phosphatase or bilirubin were observed in 15%, 11%, 11% and 10% of the patients, respectively, in the absence of progressive liver metastasis. Transient Grade 3 were observed in 0%, 0%, 0% and 1% of the patients, respectively. No Grade 4 was observed.</p><p>&nbsp;</p><p>Increases of amylase and/or lipase have been very rarely reported.</p><p>&nbsp;</p><p>Rare cases of hypokalaemia and hyponatraemia<strong> </strong>mostly related with diarrhoea and vomiting have been reported.</p><p>&nbsp;</p><p><u>Other Adverse Events Reported in Clinical Studies with the Weekly Regimen for Irinotecan</u></p><p>&nbsp;</p><p>The following additional drug-related events have been reported in clinical studies with irinotecan: pain, sepsis, anorectal disorder, GI candida infection, hypomagnesaemia, rash, skin signs, gait disturbance, confusion, headache, syncope, flushing, bradycardia, urinary tract infection, breast pain, gamma-glutamyltransferase increased, extravasation, and tumour lysis syndrome, cardiovascular disorders (angina pectoris, cardiac arrest, myocardial infarction, myocardial ischaemia, peripheral vascular disorder, vascular disorder), and thromboembolic events (arterial thrombosis, cerebral infarction, cerebrovascular accident, deep vein thrombosis, peripheral embolism, pulmonary embolism, thrombophlebitis, thrombosis, and sudden death) (see section 4.4).</p><p>&nbsp;</p><p><u>Post-Marketing Surveillance</u></p><p>&nbsp;</p><p>Frequencies from post-marketing surveillance are not known (cannot be estimated from available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pseudomembranous colitis one of which has been documented bacteriologically (<em>Clostridium difficile</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sepsis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections<sup>*</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viral infections<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia with antiplatelet antibodies</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration (due to diarrhoea and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypovolaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Speech disorder generally transient in nature, in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of irinotecan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paraesthesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscular contractions involuntary</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension (during or after infusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardio circulatory failure<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial lung disease presenting as lung infiltration is uncommon during irinotecan therapy; early effects such as dyspnoea have been reported (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal obstruction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ileus: cases of ileus without preceding colitis have also been reported</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Megacolon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal haemorrhage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colitis; in some cases, colitis was complicated by ulceration, bleeding, ileus, or infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Typhlitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colitis ischaemic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colitis ulcerative</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic or asymptomatic pancreatic enzymes increased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal perforation</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steatohepatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic steatosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reaction</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cramps</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment and acute renal failure generally in patients who become infected and/or volume depleted from severe gastrointestinal toxicities<sup>&Dagger;</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal insufficiency<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion site reaction</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amylase increased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lipase increased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatraemia mostly related with diarrhoea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transaminases increased (i.e. AST and ALT) in the absence of progressive liver metastasis have been very rarely reported.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>*&nbsp;</sup>e.g. Pneumocystis jirovecii pneumonia, bronchopulmonary aspergillosis, systemic candida.</p><p><sup>&dagger;&nbsp;</sup>e.g. Herpes zoster, influenza, hepatitis B reactivation, cytomegalovirus colitis.</p><p><sup>&Dagger;&nbsp;</sup>Infrequent cases of renal insufficiency, hypotension or cardio circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or sepsis.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&nbsp;</p><p><strong>To Report any side effects:</strong></p><p>Saudi Arabia:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>SFDA Call center : 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>There have been reports of overdose, with doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrhoea.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>There is no known antidote for irinotecan. Maximum supportive treatment should be initiated to prevent dehydration due to diarrhoea and to treat any infectious complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cytostatic topoisomerase I inhibitor. ATC Code: &nbsp;L01CE02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p><em>Experimental data:</em></p><p>&nbsp;</p><p>Irinotecan is a semisynthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase&nbsp;I. It is metabolised by carboxylesterases in most tissues to SN-38, which was found to be more active than irinotecan in purified topoisomerase&nbsp;I and more cytotoxic than irinotecan against several murine and human tumour cell lines. The inhibition of DNA topoisomerase&nbsp;I by irinotecan or SN-38 induces single strand DNA lesions which blocks the DNA replication fork and are responsible for the cytotoxicity. This cytotoxic activity was found time dependent and was specific to the S-phase.</p><p>&nbsp;</p><p><em>In vitro</em>, irinotecan and SN-38 are not found to be significantly recognised by the P-glycoprotein MDR, and displays cytotoxic activities against doxorubicin and vinblastine resistant cell lines.</p><p>&nbsp;</p><p>Furthermore, irinotecan has a broad antitumor activity <em>in vivo</em> against murine tumour models (P03 pancreatic ductal adenocarcinoma, MA16/C mammary adenocarcinoma, C38 and C51 colon adenocarcinomas) and against human xenografts (Co-4 colon adenocarcinoma, MX-1 mammary adenocarcinoma, ST-15 and SC-16 gastric adenocarcinomas). Irinotecan is active against tumours expressing P-glycoprotein MDR (vincristine‑ and doxorubicin‑resistant P388 leukaemias).</p><p>&nbsp;</p><p>Beside the antitumor activity of irinotecan, the most relevant pharmacological effect of irinotecan is the inhibition of acetylcholinesterase.</p><p>&nbsp;</p><p><em>Clinical data:</em></p><p>&nbsp;</p><p><em><u>In combination therapy for the first-line treatment of metastatic colorectal carcinoma</u></em></p><p>&nbsp;</p><p><em>In combination therapy with Folinic Acid and 5-Fluorouracil:</em></p><p>A phase III study was performed in 385 previously untreated metastatic colorectal cancer patients treated with either every 2&nbsp;weeks schedule (see section 4.2) or weekly schedule regimens. In the every&nbsp;2&nbsp;weeks schedule, on day&nbsp;1, the administration of irinotecan at 180 mg/m<sup>2</sup> once every 2&nbsp;weeks is followed by infusion with folinic acid (200 mg/m<sup>2</sup> over a 2-hour intravenous infusion) and 5‑fluorouracil (400&nbsp;mg/m<sup>2</sup> as an intravenous bolus, followed by 600 mg/m<sup>2</sup> over a 22-hour intravenous infusion). On day 2, folinic acid and 5‑fluorouracil are administered at the same doses and schedules. In the weekly schedule, the administration of irinotecan at 80 mg/m<sup>2</sup> is followed by infusion with folinic acid (500 mg/m<sup>2</sup> over a 2-hour intravenous infusion) and then by 5‑fluorouracil (2,300 mg/m<sup>2</sup> over a 24-hour intravenous infusion) over 6 weeks.</p><p>&nbsp;</p><p>In the combination treatment trial with the 2 regimens described above, the efficacy of irinotecan was evaluated in 198&nbsp;treated patients:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Combined regimens</strong></p><p><strong>(n=198)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Weekly schedule</strong></p><p><strong>(n=50)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Every&nbsp;2&nbsp;weeks schedule (n=148)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IRIN + 5FU/FA</strong></p></td><td style="vertical-align:top"><p><strong>5FU/FA</strong></p></td><td style="vertical-align:top"><p><strong>IRIN + 5FU/FA</strong></p></td><td style="vertical-align:top"><p><strong>5FU/FA</strong></p></td><td style="vertical-align:top"><p><strong>IRIN + 5FU/FA</strong></p></td><td style="vertical-align:top"><p><strong>5FU/FA</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Response rate (%)</p></td><td style="vertical-align:top"><p>40.8 *</p></td><td style="vertical-align:top"><p>23.1 *</p></td><td style="vertical-align:top"><p>51.2 *</p></td><td style="vertical-align:top"><p>28.6 *</p></td><td style="vertical-align:top"><p>37.5 *</p></td><td style="vertical-align:top"><p>21.6 *</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>p &lt; 0.001</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.045</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.005</p></td></tr><tr><td style="vertical-align:top"><p>Median time to progression (months)</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>p &lt; 0.001</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Median duration of response (months)</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>9.5</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.043</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:top"><p>Median duration of response and stabilisation (months)</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>5.6</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>p &lt; 0.001</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.003</p></td></tr><tr><td style="vertical-align:top"><p>Median time to treatment failure (months)</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.0014</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td><td colspan="2" style="vertical-align:top"><p>p &lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Median survival (months)</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>14.0</p></td><td style="vertical-align:top"><p>19.2</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>15.6</p></td><td style="vertical-align:top"><p>13.0</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.028</p></td><td colspan="2" style="vertical-align:top"><p>NS</p></td><td colspan="2" style="vertical-align:top"><p>p = 0.041</p></td></tr></tbody></table><p>IRIN: irinotecan</p><p>5FU: 5-fluorouracil</p><p>FA: folinic acid</p><p>NS: Non Significant</p><p>*: As per protocol population analysis</p><p><strong>&nbsp;</strong></p><p>In the weekly schedule, the incidence of severe diarrhoea was 44.4% in the patients treated by irinotecan in combination with 5FU/FA, and 25.6% in the patients treated by 5FU/FA alone. The incidence of severe neutropenia (neutrophil count &lt;&nbsp;500 cells/mm<sup>3</sup>) was 5.8% in the patients treated by irinotecan in combination with 5FU/FA and 2.4% in the patients treated by 5FU/FA alone.</p><p>&nbsp;</p><p>Additionally, the median time to definitive performance status deterioration was significantly longer in irinotecan combination group than in 5FU/FA alone group (p = 0.046).</p><p>&nbsp;</p><p>Quality of life was assessed in this phase III study by using the EORTC QLQ-C30 questionnaire. Time to definitive deterioration constantly occurred later in the irinotecan groups. The evolution of the Global Health Status/Quality of life was slightly better in the irinotecan combination group although not significant, showing that efficacy of irinotecan in combination treatment could be reached without affecting the quality of life.</p><p>&nbsp;</p><p><em>In combination therapy with </em><em>bevacizumab:</em></p><p>A phase III randomised, double-blind, active-controlled clinical trial evaluated bevacizumab in combination with irinotecan/5FU/FA as first-line treatment for metastatic carcinoma of the colon or rectum (Study AVF2107g). The addition of bevacizumab to the combination of irinotecan/5FU/FA resulted in a statistically significant increase in overall survival. The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease. Refer also to the bevacizumab summary of product characteristics. The efficacy results of Study AVF2107g are summarised in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>AVF2107g</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Arm 1</strong></p><p><strong>Irinotecan/5FU/FA/placebo</strong></p></td><td style="vertical-align:top"><p><strong>Arm 2</strong></p><p><strong>Irinotecan/5FU/FA/</strong><strong>Bevacizumab</strong><strong><sup>a</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number of Patients</p></td><td><p>411</p></td><td><p>402</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td><p>15.6</p></td><td><p>20.3</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td><p>14.29 &ndash; 16.99</p></td><td><p>18.46 &ndash; 24.18</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p></td><td><p>&nbsp;</p></td><td><p>0.660</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td><p>&nbsp;</p></td><td><p>0.00004</p></td></tr><tr><td style="vertical-align:top"><p>Progression-free survival</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td><p>6.2</p></td><td><p>10.6</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p></td><td><p>&nbsp;</p></td><td><p>0.54</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td><p>&nbsp;</p></td><td><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate (%)</p></td><td><p>34.8</p></td><td><p>44.8</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td><p>30.2 &ndash; 39.6</p></td><td><p>39.9 &ndash; 49.8</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td><p>&nbsp;</p></td><td><p>0.0036</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td><p>7.1</p></td><td><p>10.4</p></td></tr><tr><td style="vertical-align:top"><p>25 &ndash; 75 percentile (months)</p></td><td><p>4.7 &ndash; 11.8</p></td><td><p>6.7 &ndash; 15.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> 5 mg/kg every 2 weeks.</p><p><sup>b</sup> Relative to control arm.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>In combination therapy with </em><em>cetuximab:</em></p><p>EMR 62 202-013: This randomised study in patients with metastatic colorectal cancer who had not received prior treatment for metastatic disease compared the combination of cetuximab and irinotecan plus infusion of 5-fluorouracil/folinic acid (5FU/FA) (599 patients) to the same chemotherapy alone (599 patients). The proportion of patients with <em>KRAS</em> <em>wild‑type</em> tumours from the patient populations evaluable for KRAS status comprised 64%.</p><p>&nbsp;</p><p>The efficacy data generated in this study are summarised in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Overall population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>KRAS wild-type population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Variable/statistic</strong></p></td><td style="vertical-align:top"><p><strong>Cetuximab plus FOLFIRI (N=599)</strong></p></td><td style="vertical-align:top"><p><strong>FOLFIRI</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N=599)</strong></p></td><td style="vertical-align:top"><p><strong>Cetuximab plus FOLFIRI (N=172)</strong></p></td><td style="vertical-align:top"><p><strong>FOLFIRI</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N=176)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ORR</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>% (95% CI)</p></td><td style="vertical-align:bottom"><p>46.9 (42.9, 51.0)</p></td><td style="vertical-align:bottom"><p>38.7 (34.8, 42.8)</p></td><td style="vertical-align:bottom"><p>59.3 (51.6, 66.7)</p></td><td style="vertical-align:bottom"><p>43.2 (35.8, 50.9)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:bottom"><p>0.0038</p></td><td colspan="2" style="vertical-align:bottom"><p>0.0025</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2" style="vertical-align:bottom"><p>0.85 (0.726, 0.998)</p></td><td colspan="2" style="vertical-align:bottom"><p>0.68 (0.501, 0.934)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:bottom"><p>0.0479</p></td><td colspan="2" style="vertical-align:bottom"><p>0.0167</p></td></tr></tbody></table><p>CI = confidence interval, FOLFIRI = irinotecan plus infusion of 5FU/FA, ORR = objective response rate (patients with complete response or partial response), PFS = progression-free survival time.</p><p>&nbsp;</p><p><em>In combination therapy with </em><em>capecitabine:</em></p><p>Data from a randomised, controlled phase III study (CAIRO) support the use of capecitabine at a starting dose of 1,000 mg/m<sup>2</sup> for 2 weeks every 3 weeks in combination with irinotecan for the first‑line treatment of patients with metastatic colorectal cancer. Eight hundred twenty (820) patients were randomised to receive either sequential treatment (n = 410) or combination treatment (n = 410). Sequential treatment consisted of first-line treatment with capecitabine (1,250 mg/m<sup>2</sup> twice daily for 14&nbsp;days), second-line irinotecan (350 mg/m<sup>2</sup> on day 1), and third-line combination of capecitabine (1,000 mg/m<sup>2</sup> twice daily for 14 days) with oxaliplatin (130 mg/m<sup>2</sup> on day 1). Combination treatment consisted of first-line treatment of capecitabine (1,000 mg/m<sup>2</sup> twice daily for 14&nbsp;days) combined with irinotecan (250 mg /m<sup>2</sup> on day 1) (XELIRI) and second-line capecitabine (1,000 mg/m<sup>2</sup> twice daily for 14 days) plus oxaliplatin (130 mg/m<sup>2</sup> on day 1). All treatment cycles were administered at intervals of 3 weeks. In first-line treatment, the median progression-free survival in the intent‑to‑treat population was 5.8 months (95%&nbsp;CI, 5.1‑6.2&nbsp;months) for capecitabine monotherapy and 7.8 months (95% CI, 7.0-8.3 months) for XELIRI (p = 0.0002).</p><p>&nbsp;</p><p>Data from an interim analysis of a multicentre, randomised, controlled phase II study (AIO KRK 0604) support the use of capecitabine at a starting dose of 800&nbsp;mg/m<sup>2</sup> for 2 weeks every 3 weeks in combination with irinotecan and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer. One hundred fifteen (115) patients were randomised to treatment with capecitabine combined with irinotecan (XELIRI) and bevacizumab: capecitabine (800 mg/m<sup>2</sup> twice daily for 2&nbsp;weeks, followed by a 7-day rest period), irinotecan (200 mg/m<sup>2</sup> as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1&nbsp;every 3 weeks); a total of 118 patients were randomised to treatment with capecitabine combined with oxaliplatin plus bevacizumab: capecitabine (1,000&nbsp;mg/m<sup>2</sup> twice daily for two weeks followed by a 7‑day rest period), oxaliplatin (130 mg/m<sup>2</sup> as a 2 hour infusion on day 1 every 3&nbsp;weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks). Progression-free survival at 6 months in the intent‑to‑treat population was 80% (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab). Overall response rate (complete response plus partial response) was 45% (XELOX plus bevacizumab) versus 47% (XELIRI plus bevacizumab).</p><p>&nbsp;</p><p><em><u>In monotherapy for the second-line treatment of metastatic colorectal carcinoma</u></em></p><p>&nbsp;</p><p>Clinical phase II/III studies were performed in more than 980&nbsp;patients in the every 3‑week dosage schedule with metastatic colorectal cancer who failed a previous 5FU regimen. The efficacy of irinotecan was evaluated in 765 patients with documented progression on 5FU at study entry.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:107%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Phase III</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Irinotecan versus supportive care</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Irinotecan versus 5FU</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Irinotecan</strong></p><p><strong>&nbsp;</strong></p><p><strong>n = 183</strong></p></td><td style="vertical-align:top"><p><strong>Supportive care</strong></p><p><strong>n = 90</strong></p></td><td style="vertical-align:top"><p><strong>p‑values</strong></p></td><td style="vertical-align:top"><p><strong>Irinotecan</strong></p><p><strong>&nbsp;</strong></p><p><strong>n = 127</strong></p></td><td style="vertical-align:top"><p><strong>5FU</strong></p><p><strong>&nbsp;</strong></p><p><strong>n = 129</strong></p></td><td style="vertical-align:top"><p><strong>p‑values</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pregression‑Free Survival at 6&nbsp;months (%)</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>&nbsp;</p></td><td><p>33.5*</p></td><td><p>26.7</p></td><td><p>p&nbsp;=&nbsp;0.03</p></td></tr><tr><td style="vertical-align:top"><p>Survival at 12&nbsp;months (%)</p></td><td><p>36.2*</p></td><td><p>13.8</p></td><td><p>p&nbsp;=&nbsp;0.0001</p></td><td><p>44.8*</p></td><td><p>32.4</p></td><td><p>p&nbsp;=&nbsp;0.0351</p></td></tr><tr><td style="vertical-align:top"><p>Median survival (months)</p></td><td><p>9.2*</p></td><td><p>6.5</p></td><td><p>p&nbsp;=&nbsp;0.0001</p></td><td><p>10.8*</p></td><td><p>8.5</p></td><td><p>p&nbsp;=&nbsp;0.0351</p></td></tr></tbody></table><p>NA&nbsp;=&nbsp;Not applicable</p><p>*&nbsp;Statistically significant difference</p><p>&nbsp;</p><p>In phase II studies, performed on 455 patients in the every-3-week dosage schedule, the progression‑free survival at 6 months was 30% and the median survival was 9 months. The median time to progression was 18 weeks.</p><p>&nbsp;</p><p>Additionally, non-comparative phase II studies were performed in 304 patients treated with a weekly schedule regimen, at a dose of 125 mg/m<sup>2</sup> administered as an intravenous infusion over 90 minutes for 4&nbsp;consecutive weeks followed by 2 weeks rest. In these studies, the median time to progression was 17&nbsp;weeks and median survival was 10 months. A similar safety profile has been observed in the weekly‑dosage schedule in 193&nbsp;patients at the starting dose of 125 mg/m<sup>2</sup>, compared to the every&nbsp;3‑week‑dosage schedule. The median time of onset of the first liquid stool was on day 11.</p><p><em>&nbsp;</em></p><p><em><u>In combination with </u></em><em><u>cetuximab</u></em><em><u> after failure of </u></em><em><u>irinotecan</u></em><em><u>-including cytotoxic therapy</u></em></p><p>&nbsp;</p><p>The efficacy of the combination of cetuximab with irinotecan was investigated in two clinical studies. A total of 356 patients with EGFR-expressing metastatic colorectal cancer who had recently failed irinotecan‑including cytotoxic therapy and who had a minimum Karnofsky performance status of 60, but the majority of whom had a Karnofsky performance status of &ge;&nbsp;80 received the combination treatment.</p><p>&nbsp;</p><p>EMR 62 202-007: This randomised study compared the combination of cetuximab and irinotecan (218&nbsp;patients) with cetuximab monotherapy (111&nbsp;patients).</p><p>&nbsp;</p><p>IMCL CP02-9923: This single arm open-label study investigated the combination therapy in 138&nbsp;patients.</p><p>&nbsp;</p><p>The efficacy data from these studies are summarised in the table below.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><thead><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ORR</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>DCR</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PFS (months)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>OS (months)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>n</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>n</strong><strong> </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>95</strong><strong>%</strong></p><p><strong>CI</strong></p></td><td style="vertical-align:top"><p><strong>Median</strong></p></td><td style="vertical-align:top"><p><strong>95</strong><strong>%</strong></p><p><strong>CI</strong></p></td><td style="vertical-align:top"><p><strong>Median</strong></p></td><td style="vertical-align:top"><p><strong>95</strong><strong>% </strong></p><p><strong>CI</strong></p></td></tr></thead><tbody><tr><td colspan="10" style="vertical-align:top"><p>Cetuximab + Irinotecan</p></td></tr><tr><td style="vertical-align:top"><p>EMR 62 202-007</p></td><td style="vertical-align:top"><p>218</p></td><td style="vertical-align:top"><p>50</p><p>(22.9)</p></td><td style="vertical-align:top"><p>17.5,</p><p>29.1</p></td><td style="vertical-align:top"><p>121</p><p>(55.5)</p></td><td style="vertical-align:top"><p>48.6,</p><p>62.2</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>2.8,</p><p>4.3</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>7.6,</p><p>9.6</p></td></tr><tr><td style="vertical-align:top"><p>IMCL CP02-9923</p></td><td style="vertical-align:top"><p>138</p></td><td style="vertical-align:top"><p>21 (15.2)</p></td><td style="vertical-align:top"><p>9.7,</p><p>22.3</p></td><td style="vertical-align:top"><p>84</p><p>(60.9)</p></td><td style="vertical-align:top"><p>52.2,</p><p>69.1</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>2.6,</p><p>4.1</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>7.2,</p><p>10.3</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>Cetuximab</p></td></tr><tr><td style="vertical-align:top"><p>EMR 62 202-007</p></td><td style="vertical-align:top"><p>111</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>12</p><p>(10.8)</p></td><td style="vertical-align:top"><p>5.7,</p><p>18.1</p></td><td style="vertical-align:top"><p>36</p><p>(32.4)</p></td><td style="vertical-align:top"><p>23.9,</p><p>42.0</p></td><td style="vertical-align:top"><p>1.5</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.4,</p><p>2.0</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>5.6,</p><p>9.1</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p>CI = confidence interval; DCR = disease control rate (patients with complete response, partial response, or stable disease for at least 6 weeks); ORR = objective response rate (patients with complete response or partial response); OS = overall survival time; PFS = progression-free survival.</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of the combination of cetuximab with irinotecan was superior to that of cetuximab monotherapy, in terms of objective response rate (ORR), disease control rate (DCR) and progression‑free survival (PFS). In the randomised trial, no effects on overall survival were demonstrated (hazard ratio 0.91, p = 0.48).</p><p>&nbsp;</p><p><em><u>Patients with Reduced UGT1A1 Activity</u></em></p><p>&nbsp;</p><p>Uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) is involved in the metabolic deactivation of SN-38, the active metabolite of irinotecan to inactive SN-38 glucuronide (SN-38G). The UGT1A1 gene is highly polymorphic, resulting in variable metabolic capacities among individuals. One specific variation of the UGT1A1 gene includes a polymorphism in the promoter region known as the UGT1A1*28 variant. This variant and other congenital deficiencies in UGT1A1 expression (such as Crigler-Najjar and Gilbert&#39;s syndrome) are associated with reduced activity of this enzyme. Data from a meta‑analysis indicate that individuals with Crigler-Najjar syndrome (types 1 and 2) or those who are homozygous for the UGT1A1*28 allele (Gilbert&rsquo;s syndrome) are at increased risk of haematological toxicity (Grades 3 and 4) following administration of irinotecan at moderate or high doses (&gt;&nbsp;150 mg/m<sup>2</sup>). A relationship between UGT1A1 genotype and the occurrence of irinotecan induced diarrhoea was not established.</p><p>&nbsp;</p><p>Patients known to be homozygous for UGT1A1*28 should be administered the normally indicated irinotecan starting dose. However, these patients should be monitored for haematologic toxicities. A reduced irinotecan starting dose should be considered for patients who have experienced prior haematologic toxicity with previous treatment. The exact reduction in starting dose in this patient population has not been established and any subsequent dose modifications should be based on a patient&#39;s tolerance of the treatment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>There is at present insufficient data to conclude on clinical utility of UGT1A1 genotyping.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><strong>&nbsp;</strong></p><p>At the end of the infusion, with the recommended dose of 350 mg/m<sup>2</sup>, the mean peak plasma concentrations of irinotecan and SN-38 were 7.7 &micro;g/ml and 56 ng/ml, respectively, and the mean area under the curve (AUC) values were 34&nbsp;&mu;g.h/ml and 451 ng.h/ml, respectively. A large interindividual variability in pharmacokinetic parameters is generally observed for SN-38.</p><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p><strong>&nbsp;</strong></p><p>The phase I study in 60 patients with a dosage regimen of a 30-minute intravenous infusion of 100 to 750 mg/m<sup>2</sup> every three weeks, the volume of distribution at steady state (Vss): 157 L/m<sup>2</sup>.</p><p>&nbsp;</p><p><em>In vitro</em>, plasma protein binding for irinotecan and SN-38 was approximately 65% and 95%, respectively.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Mass balance and metabolism studies with 14C‑labelled drug have shown that more than 50% of an intravenously administered dose of irinotecan is excreted as unchanged drug, 33% in the faeces mainly via the bile, and 22% in urine.</p><p>&nbsp;</p><p>Two metabolic pathways account each for at least 12% of the dose:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrolysis by carboxylesterase into active metabolite SN‑38, SN‑38 is mainly eliminated by glucuronidation and further by biliary and renal excretion (less than 0.5% of the irinotecan dose). The SN-38-glucuronite is subsequently probably hydrolysed in the intestine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytochrome P450 3A enzymes‑dependent oxidations resulting in opening of the outer piperidine ring with formation of APC (aminopentanoic acid derivate) and NPC (primary amine derivate) (see section 4.5).</p><p>&nbsp;</p><p>Unchanged irinotecan is the major entity in plasma, followed by APC, SN‑38-glucuronide and SN‑38. Only the SN-38 has a significant cytotoxic activity.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>In a phase I study in 60 patients with a dosage regimen of a 30‑minute intravenous infusion of 100 to 750 mg/m<sup>2</sup>, every three weeks, irinotecan showed a biphasic or triphasic elimination profile. The mean plasma clearance was 15 L/h/m<sup>2</sup>. The mean plasma half-life of the first phase of the triphasic model was 12&nbsp;minutes, of the second phase 2.5 hours, and the terminal phase half-life was 14.2&nbsp;hours. SN-38 showed a biphasic elimination profile with a mean terminal elimination half-life of 13.8 hours.</p><p><u>&nbsp;</u></p><p>Irinotecan clearance is decreased by about 40% in patients with bilirubinemia between 1.5 and 3 times the upper normal limit. In these patients a 200 mg/m<sup>2</sup> irinotecan dose leads to plasma drug exposure comparable to that observed at 350 mg/m<sup>2</sup> in cancer patients with normal liver parameters.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>A population pharmacokinetic analysis of irinotecan has been performed in 148 patients with metastatic colorectal cancer, treated with various schedules and at different doses in phase II trials. Pharmacokinetic parameters estimated with a three compartment model were similar to those observed in phase I studies. All studies have shown that irinotecan (CPT-11) and SN-38 exposure increase proportionally with CPT-11 administered dose; their pharmacokinetics are independent of the number of previous cycles and of the administration schedule.</p><p>&nbsp;</p><p><u>Pharmacokinetic/Pharmacodynamic relationship(s)</u></p><p><u>&nbsp;</u></p><p>The intensity of the major toxicities encountered with irinotecan (e.g. leukoneutropenia and diarrhoea) are related to the exposure (AUC) to parent drug and metabolite SN-38. Significant correlations were observed between haematological toxicity (decrease in white blood cells and neutrophils at nadir) or diarrhoea intensity and both irinotecan and metabolite SN-38 AUC values in monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irinotecan and SN-38 have been shown to be mutagenic <em>in vitro</em> in the chromosomal aberration test on CHO‑cells as well as in the <em>in vivo</em> micronucleus test in mice.</p><p>&nbsp;</p><p>However, they were shown to be devoid of any mutagenic potential in the Ames test.</p><p>&nbsp;</p><p>In rats treated once a week during 13 weeks to a maximum dose of 150 mg/m<sup>2</sup> (which is less than half the human recommended dose), no treatment related tumours were reported 91&nbsp;weeks after the end of treatment.</p><p>&nbsp;</p><p>Single‑ and repeated‑dose toxicity studies with irinotecan have been carried out in mice, rats and dogs. The main toxic effects were seen in the haematopoietic and lymphatic systems. In dogs, delayed diarrhoea associated with atrophy and focal necrosis of the intestinal mucosa was reported. Alopecia was also observed in the dog.</p><p>&nbsp;</p><p>The severity of these effects was dose‑related and reversible.</p><p>&nbsp;</p><p><u>Reproduction</u></p><p><u>&nbsp;</u></p><p>Irinotecan was teratogenic in rats and rabbits at doses below the human therapeutic dose. In rats, pups born to treated animals with external abnormalities showed a decrease in fertility. This was not seen in morphologically normal pups. In pregnant rats there was a decrease in placental weight and in the offspring a decrease in foetal viability and increase in behavioural abnormalities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sorbitol (E420)</p><p>Lactic acid (E270)</p><p>Sodium hydroxide and/or hydrochloric acid (for pH adjustment)</p><p>Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Irinotecan Hospira after the expiry date which is stated on the carton  label    
            after EXP: The expiry date refers to the last day of that month.
unopened vials is 3 years.

Once opened, vials of irinotecan for injections should be used immediately as they contain no antimicrobial preservatives.

Stability after dilution

Chemical and physical in-use stability has been demonstrated in glucose 50 mg/ml (5%) and in sodium chloride 9 mg/ml (0.9%) for 72 hours at 2 to 8 °C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

Do not use this medicine if you notice particles visible in the concentrate or infusion solution.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep vials in the outer carton in order to protect from light. Do not freeze.</p><p>The vials Irinotecan Hydrochloride concentrate for solution for infusion shall be kept protected from light.</p><p>Do not store above 30&deg;C, Do not freeze<br />&nbsp;</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 ml in Onco-Tain&reg; Type 1 brown glass vial, with a fluorobutyl rubber closure coated with Teflon on the inner side.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 ml in Onco-Tain&reg; Type 1 brown glass vial, with a fluorobutyl rubber closure coated with Teflon on the inner side.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ml in Onco-Tain&reg; Type 1 brown glass vial, with a fluorobutyl rubber closure coated with Teflon on the inner side.</p><p>&nbsp;</p><p>Each pack contains 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution must be diluted before use. For single use only. Any remaining solution should be discarded.</p><p>&nbsp;</p><p>The appearance of the product after dilution is a clear, colourless to pale yellow solution free from visible matter.</p><p>&nbsp;</p><p>As with other antineoplastic agents, irinotecan infusions must be prepared and handled with caution. The use of glasses, mask and gloves is required.</p><p>&nbsp;</p><p>Pregnant women should not handle cytotoxics.</p><p>&nbsp;</p><p>If irinotecan concentrate or infusion solutions should come into contact with the skin, wash immediately and thoroughly with soap and water. If irinotecan concentrate or infusion solutions should come into contact with the mucous membranes, wash immediately with water.</p><p><em>&nbsp;</em></p><p><u>Preparation for the intravenous infusion administration</u></p><p>&nbsp;</p><p>As with any other injectable medicinal product, irinotecan infusion must be prepared aseptically (see section 6.3).</p><p>&nbsp;</p><p>If any precipitate is observed in the vials or in the infusion solution, the product must be discarded according to standard procedures for cytotoxic agents.</p><p>&nbsp;</p><p>Aseptically withdraw the required amount of irinotecan concentrate from the vial with a calibrated syringe and inject into a 250 ml infusion bag or bottle containing <u>either</u> 9 mg/ml (0.9%) sodium chloride solution or 50 mg/ml (5%) glucose solution only. The infusion should then be thoroughly mixed by manual rotation.</p><p>&nbsp;</p><p><u>Disposal</u></p><p><em>&nbsp;</em></p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hospira UK Limited, United Kingdom

Manufacturer:
        -    Zydus Hospira Oncology Private Limited ZHOPL, Ahmedabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>